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INTRODUCTION 
The oral cavity is made of complex structures that include the lips, tongue, 
gingivae, alveolus, and palate, floor of the mouth, mucous lining membrane and 
minor salivary glands. Like elsewhere in the body, these structures are made of 
fundamental tissues like blood vessels, nerves, bones, muscles, mucous 
membrane and skin. Malignancy may arise from any of these structures. The 
tissues of the oral cavity are exposed to a wide variety of infectious, chemical 
irritants and carcinogens and thus are liable to develop a wide variety of 
malignancies.1-3 
Cancers of the oral cavity are notorious for their poor prognosis and outcome 
inspite of advances in treatment. Majority of the patients are seen in an 
advanced stage of presentation and treatment of these patients is very 
demanding which is predominantly by a multimodal approach.  95% of oral 
cavity cancers are squamous cell cancers4 and it is one of the most important 
health burdens in India. 
      This study aims to analyze the incidence of oral cavity cancers in different 
age groups, sexes, occupation, sites, the association of risk factors with oral 
cancers, determine the average presenting stage and to discuss the various 
clinical presentations, modalities of treatment and their outcomes.  
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AIM OF THE STUDY 
 
This study aims to 
• To analyses the incidence (Age, Sex, Occupation, Site and Histology).  
• To discuss the association of risk factors with oral cancers,             
• To find presenting stage at the time of hospital visit,  
• To discuss the various clinical presentation,  
• Various modalities of treatment and their outcomes. 
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EPIDEMIOLOGY 
Cancer of the oral cavity ranks among the ten most common cancers in the 
world with marked geographical variation.42-6 % of all cancers diagnosed in 
US are oral cavity cancers which by themselves accounts for more than 30% of 
all head and neck cancers. In the US alone more than 30950 new cases of oral 
cavity cancer and 4000-8000 deaths are reported each year.5 
Worldwide there is great variation in the incidence of oral cancer. In Western 
Europe and Australia the incidence closely resembles that of the US. The 
highest rates of oral cavity cancers are to be found in France, India, Brazil, 
central and Eastern Europe. Regional variation in the incidence of oral cancers 
is predominantly due to differing social customs. 
Males are affected two to three times more than females. This can be attributed 
to their higher intake of tobacco, alcohol and sunlight exposure. This trend is 
presently changing as the number of women using tobacco is on the rise.6 
Rates of oral cavity cancer are higher in India than any other country in Asia7 
and accounts for 40% of all cancers.8In parts of Asia the habit of chewing pan is 
thought to be the principal cause of oral cancer. The practice of reverse smoking 
which is common in India, contributes to the higher incidence of cancers of the 
hard palate. Females in India have a higher incidence of oral cavity cancers than 
males due to their practice of chewing betel nuts.8 
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     The greatest number of cases in both males and females occur in the sixth 
decade of life. The mean age of diagnosis is 57 years in males and 52.5 years in 
females. The incidence among the young appears to be increasing. In Europe 
and North America the current trend of binge drinking and acute tobacco abuse 
has been observed to correlate with the rising incidence of cancer of the tongue 
in young people.8 
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ANATOMY OF THE ORAL CAVITY 
The oral cavity encompasses the area from the vermillion border of the lip to an 
imaginary plane drawn at the junction of the hard palate and the soft palate 
superiorly, the circumvallate papillae and the anterior tonsillar pillars 
posteriorly.It comprises of seven anatomic subsites which are (Fig.1&2) 
1. Lip 
2. Buccal mucosa 
3. Alveolar ridges 
4. Floor of the mouth 
5. Anterior two thirds of the tongue. 
6. Retromolar trigone 
7. Hard palate 
Oral cavity is divided into an outer smaller portion called the 1). Vestibule and 
the inner larger part the 2).Oral cavity proper. 
VESTIBULE 
Vestibule of the mouth is a narrow space bounded externally by the lips and the 
cheeks and internally by the gums and the teeth. It communicates with the 
exterior through the oral fissure and with the mouth open it communicates 
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freely with the oral cavity proper. Even when the mouth is tightly closed there 
remains a small communication behind the third molar tooth. 
     The parotid duct opens on the inner surface of the cheek opposite the crown 
of the upper second molar tooth. Numerous labial and buccal glands situated in 
the sub mucosa of the lips and cheek open into the vestibule. Four to five molar 
glands situated in the buccopharyngeal fascia also open into the vestibule. 
Except for the teeth the entire vestibule is lined by mucous membrane. The 
mucous folds that pass from the lips to the gums are called the frenulum of the 
lip. 
LIPS 
The lips are mobile musculofibrous folds that surround the mouth externally 
and are lined externally by skin and internally by mucous membrane. Each lip is 
composed of skin, superficial fascia, orbicularis oris muscle, the submucosa 
containing mucous labial glands and mucous membrane. The lips are bound to 
the oral fissure where they meet laterally at the angle of the mouth. The inner 
surface of each lip is surrounded by a frenulum which ties it to the gum. The 
outer surface of each lip presents a vertical median groove the philtrum.The 
vermilion border represents the transitional border of the lips where the lips 
merge into the mucous membrane. 
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CHEEK 
The cheeks are fleshy flaps forming a large part of each side of the face. Each 
cheek is composed of skin, superficial fascia containing some facial muscles, 
the parotid duct, mucous molar gland, vessels and nerves, buccinators covered 
by the buccopharyngeal fascia and pierced by the parotid duct, submucosa with 
mucous buccal glands and mucous membrane. 
BUCCAL MUCOSA 
The buccal mucosa includes the mucous covering of the lip and the cheeks 
extending from the line of contact of the opposing lip to the pterygomandibular 
raphe posteriorly.It extends to the line of attachment of the mucosa of the upper 
and lower alveolar ridge superiorly and inferiorly. The buccinators muscle 
forms the lateral margin of the vestibule. Cancer extending through the 
buccinator muscle can involve the buccal pad of fat, subcutaneous tissue and 
skin over the cheek. 
ALVEOLAR RIDGE  
The alveolar ridge includes the alveolar processes of the mandible, mucosa and 
the overlying mucosal covering. The lower alveolar ridge extends to the 
ascending ramus of the mandible posteriorly.The mucosal covering of the lower 
alveolar ridge extends from the buccal sulcus to the floor of mouth. The 
mucosal covering of the upper alveolar ridge extends from the buccal sulcus to 
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the hard palate posteriorly.The superior alveolar ridge extends posteriorly upto 
the superior end of the pterygopalatine arch. Cancers arising from the superior 
alveolar ridge extend easily into the maxillary antrum or the floor of the mouth 
because of the thin mucosal lining. 
ORAL CAVITY PROPER 
This is bound inferolaterally by the teeth the gums and the alveolar arches of the 
jaw. The roof is formed by the hard palate and the soft palate and the floor is 
occupied by the tongue which also extends posteriorly. Sublingual region is the 
region anteriorly below the tip of the tongue. The oral cavity communicates 
with the pharynx through the oropharyngeal isthmus (isthmus of fauces) which 
is bound superiorly by the soft palate, anterior by the tongue, and on each side 
by the palatoglossal arch. 
GINGIVAE 
The gingivae are composed of fibrous tissue covered with mucous membrane. 
The gingivae proper is firmly attached to the alveolar processes of the mandible, 
maxilla and the necks of the teeth; it is further divided into the superior and 
inferior lingual gingivae, maxillary and mandibular labial or buccal 
gingivae.The gingivae proper is pink stippled and keratinizing. The alveolar 
gingivae which are unattached are normally shiny red and non keratinizing. 
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FLOOR OF THE MOUTH 
The floor of the mouth is a crescent shaped space extending from the lower 
alveolar ridge to the ventral surface of the tongue. It overlies the mylohyoid and 
the hyoglossus muscles. Its posterior limit is the anterior pillar. It is divided 
anteriorly by the lingual frenulum into right and left sides. Sublingual caruncles 
are found on each side of the frenulum, anteriorly and superior portions of the 
sublingual glands are located posterolaterally. A muscular ring formed by a pair 
of mylohyoid muscles extending from the manidble laterally to the hyoid bone 
medially supports the floor of mouth anteriorly. Medially the styloglossus, 
hyoglossus and genioglossus muscles are found between the mylohyoid muscle 
and mucosa of the floor of mouth. Floor of mouth is supported posteriorly by 
the hyoglossus muscle. The sublingual gland, lingual nerve and the hypoglossal 
muscle are lateral to the hyoglossus muscle, whereas the lingual artery lies 
medial to the muscle. 
TONGUE 
The mobile two thirds of the tongue anterior to the circumvallate papillae are 
considered to be part of the oral cavity; the oral tongue includes four anatomic 
areas-the tip, lateral border, ventral and the dorsal surfaces. Six paired muscles 
form the mobile tongue-three intrinsic and three extrinsic. Extrinsic muscles 
include genioglossus, hyoglossus and styloglossus. Intrinsic muscles include 
vertical, transverse and the lingual muscles. Extrinsic muscles primarily move 
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the body of the tongue while the intrinsic muscles shape the tongue during 
swallowing and speech. 
RETROMOLAR TRIGONE 
Retromolar trigone is the triangular area overlying the ascending ramus of the 
mandible. The base of the triangle is formed by the last molar tooth and the 
apex points towards the maxillary tuberosity. The base of the triangle is 
contiguous with the gingivobuccal sulcus laterally and the gingivolingual sulcus 
medially. The lateral side of the triangle is continuous with the buccal mucosa 
while the medial side continuous into the anterior tonsillar pillars. The 
retromolar trigone is tightly attached to the underlying mandible; it is not, 
unusual for bony invasion to occur even for early stage tumours. 
HARD PALATE 
This comprises of the primary palate formed by the fusion of the palatine 
processes of the maxilla, and a secondary palate formed by the fusion of the 
horizontal lamina of the palatine bones. The hard palate extends from the inner 
surface of the superior alveolar ridge to the posterior edge of the palatine bone. 
Although the dense mucoperiosteum of the palatine bone is relatively resistant 
to tumour invasion, several pathways allow for tumour spread beyond the hard 
palate. The primary palate and the secondary palate are fused at the incisive 
fossa which acts as a pathway into the nasal cavity. Likewise the greater 
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palatine fossa allows for tumour spread into the pterygopalatine fossa and skull 
base. 
BLOOD SUPPLY OF THE ORAL CAVITY 
The entire blood supply of the oral cavity is from the three branches 
of the external carotid artery. A branch of external carotid artery, the facial 
artery, supplies the cheek. Another branch of external carotid artery, the lingual 
artery supplies the tongue. The greater palatine artery, a branch of maxillary 
artery which emerges from the greater palatine foramen supplies the palate.  
 
NERVE SUPPLY OF THE ORAL CAVITY 
The trigeminal nerve takes care of the sensory supply of the mucous membrane 
of the cheek above by maxillary division and below by the mandible 
division.The lingual nerve supplies the anterior two thirds of the tongue. The 
trigeminal component carries general sensations while the chord tympani 
component carries taste sensations. All the muscles of tongue, both intrinsic and 
extrinsic are supplied by the hypoglossal nerve except the palatoglossus muscle 
which is supplied by pharyngeal plexus. 
 
LYMPHATIC DRAINAGE  
Lymphatic drainage of the oral cavity is predominantly to the submental, 
submandibular and upper deep cervical lymphnodes especially the jugulo 
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omohyoid. Lymphatics from the central part of lower lip, anterior part of the 
floor of mouth, anterior part of gums drain into the submental lymphnodes. The 
tip of the tongue drains bilaterally to the submental lymphnodes. Lymphatics 
from the upper lip, lateral parts of the lower lip, cheek ,rest of floor of mouth, 
upper gums and posterior parts of lower gums and anterior two thirds of the 
tongue except tip drains into submandibular group. The posterior one third of 
the tongue drains bilaterally into the jugulo omohyoid nodes. Ultimately the 
lymph from the tongue reaches the jugulo omohyoid nodes.Cheek also drains 
into the preauricular, buccal and mandibular nodes. Upper lip also drains into 
the preauricular and parotid nodes. Hard palate drains into retropharyngeal and 
upper deep cervical group of nodes. 
 
PATTERN OF LYMPH NODE METASTASIS9 
Level I: Includes nodes within the submental and submandibular triangle. 
Ia: Nodes in the submental triangle which is bound bilaterally by the anterior 
bellies of digastrics, superiorly by the symphysis menti and inferiorly by the 
hyoid. 
Ib: Includes the submandibular nodes which are bound anteriorly by the 
posterior bellies and posteriorly by the anterior bellies of either digastrics and 
superiorly by the body of the mandible. 
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Level II: Includes upper jugular chain of nodes  
IIa: the jugulodigastric node which is anterior to the posterior border of 
sternocleidomastoid, posterior to posterior belly of digastrics, superior to the 
hyoid and inferior to the spinal accessory nerve.  
IIb: nodes in the submuscular recess lying superior to spinal accessory nerve to 
the skull base.  
Level III: Includes middle jugular nodes which lie inferior to hyoid, superior to 
cricoids, deep to the sternocleidomastoid along its posterior border and strap 
muscles medially. 
Level IV: Includes the lower jugular nodes which lie inferior to cricoid and 
superior to the clavicle, deep to sternocleiomastoid along its posterior border to 
strap muscles medially. 
Level V: Includes nodes in the posterior cervical triangle. 
Va: lateral to posterior aspect of sternocleidomastoid, inferior and medial to 
splenius capitis and trapezius, superior to the spinal accessory nerve. 
Vb: lateral to posterior aspect of sternocleidomastoid, medial to the trapezius, 
inferior to the spinal accessory nerve and superior to the clavicle. 
Level VI: Includes nodes in the anterior triangle of necks bound on either side 
laterally by the strap muscles, superiorly by hyoid and inferiorly by the 
suprasternal notch. 
Level VII: paratracheal nodes in the upper mediastinum which lie inferior to 
the suprasternal notch. 
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PHYSIOLOGY 
 
1. Mastication 
The tongue, teeth, palate and other structures help in digestion by making food 
easier to swallow.  
2. Speech 
Together with the pharynx it helps in speech by acting as a resonator. 
3. Respiration 
While the oral cavity has no major role to play during normal breathing, 
pathology may exaggerate its role as a conduit. 
4. Taste 
The taste buds are located in the tongue. 
5. Absorption 
The lining membrane of the mouth is highly permeable to lipid soluble 
substances and this fact can be used in the administration of certain drugs (e.g.; 
anginal, oral hypoglycaemic agents etc). 
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ETIOLOGY 
TOBACCO: 
The use of tobacco and tobacco related substances is strongly correlated with 
cancers of oral cavity. Tobacco smoke is known to have more than 300 
carcinogens,10most importantly benzpyrene and tobacco specific nitrosamines 
which on absorption produce DNA adducts and interfere with DNA replication. 
Smoking is an independent risk factor associated with 80-90%of oral cavity 
cancers.11-12 The relative risk of developing oral carcinoma is six to eight times 
more for smokers than for non smokers.11-12Cigars increase risk of cancer 4-20 
times and smoking of just two cigars a day is considered equivalent to smoking 
a pack of cigarettes.13 Pipe smoking is associated with cancer of the lip. This is 
attributed to temperature changes and permeability of the pipe stem.15Snuff 
causes hyperkeratosis, dysplasia and squamous cell carcinoma. Exposure to 
smokeless tobacco increases the risk of malignancy four fold, particularly that 
of buccal mucosa as snuff is kept between the mucosa of the cheek or lower lip 
and the jaw enabling prolonged contact times for carcinogens with mucosal 
tissues.14On eliminating its use, tobacco induced morphological changes in the 
oral mucosa and risk of cancer reverses rapidly; upto 30% for those who have 
quit smoking for 1-9 years and upto 50% for those who have quit for more than 
9 years.16In countries of Asia, particularly India the habit of chewing  a mixture 
of dried tobacco leaf, slaked lime, catechu, areca nut, condiments(pan), and 
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betel nut increases the risk of malignancy as much as 123 times.17It is usually 
kept in the gingivobuccal sulcus throughout night(night quid). Betel nut 
contains arecoline which stimulates collagen synthesis and proliferation of 
fibroblasts and tannin which stabilizes collagen fibrils. With regards to tobacco 
consumption women seem to have twice as much risk as men to develop oral 
cavity cancers.18 
ALCOHOL:                   
Cancers of the oral cavity are six times more common in people who consume 
alcohol and 70-80% of people who develop the disease give a history of alcohol 
consumption.19Heavy alcohol consumption(more than 55 drinks per week) 
actually has a greater risk than tobacco alone.20 Alcohol is an independent risk 
factor but acts synergistically with smoking.21 Cancers of the floor of mouth, a 
dependent area of the oral cavity is more common in alcoholics an smokers due 
to pooling of saliva.22Alcohol acts as a promoter, irritant, a solvent for 
carcinogens and also interferes with DNA repair after exposure to nitrosamine 
compounds.  
MARIJUANA 
There is no concrete evidence yet that there is an association between marijuana 
usage and oral cancers.26It is difficult to analyse this given fact that tobacco, 
alcohol, marijuana are often consumed together.      
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ULTRAVIOLET RADIATION:  
Prolonged exposure to sunlight causes hyperkeratosis, atrophy of fat and 
glandular elements and is a proven risk factor for carcinoma of the lip 
particularly in countries which receive abundant sunshine. Lack of pigments 
makes the lip more vulnerable to ultraviolet radiation and its deleterious effects. 
HUMAN VIRUSES: 
While it is unclear whether HSV by itself can induce cancer, it is thought to act 
as co-carcinogens with tobacco and alcohol sensitizing the oral mucosa to their 
effects.23 Some studies have demonstrated the presence of HPV in up to 50% of 
oral cancers; HPV-6 and HPV-16 are most commonly associated with oral 
cavity cancers.24 Further exposure to tobacco is necessary for inducing any 
malignant transformation.25 
DIET AND NUTRITION: 
Deficiencies of vitamins A, C, E and iron are associated with oral cavity 
malignancies. Alcoholism induced riboflavin deficiency may contribute to 
increased oral cancer rates in that population. Similarly iron deficiency induced 
atrophic changes in oral mucosa27 could be the reason behind increased oral 
cancer rates seen in Plummer Vinson syndrome. Conversely a diet rich in dark 
yellow, cruciferous, green leafy vegetables and fruits reduces the risk by 
approximately 40-60%.28 
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DENTAL FACTORS:   
People with dental caries, plaques, inflammation of the gingivae appear to have 
a greater risk when compared to the general population.29 An ill fitting denture 
could increase the risk of cancer of the tongue.30 Poor  oral hygiene is often 
associated with tobacco and alcohol abuse. Oral microflora may act on ethanol 
and convert it to acetaldehyde a known carcinogen.31 
MECHANISMS OF CARCINOGENESIS 
Oral cavity cancers have an underlying multistep carcinogenesis akin to 
Carcinoma of colon, described by Fearon and Vogelstein32where in 
precancerous polyps progress to invasive carcinoma. Some notable molecular 
alterations are: 
EGFR/TGF-α 
Increased production of these tyrosine kinase receptors is an early event in head 
and neck cancers.33 EGFR is upregulated in head and neck squamous cell 
carcinoma and this fact may be used therapeutically.34 
TP53  
Nearly 50% of head and neck cancers show mutation of TP53 gene.34 Loss of 
this gene results in defective DNA repair, accumulation of genetic defects and 
consequently transformation of preinvasive to invasive lesions.35 
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TP16 /CYCLIN D1 
These are cell cycle regulatory genes. Inactivation of TP16 is seen in early head 
and neck cancers.36 Amplification of cyclin d1 is seen in 33-68% of head and 
neck cancers.37 These events cause up regulation of cell cycle and also correlate 
with a decreased survival and disease free rates in patients with cancer of the 
tongue.38 
BAX/BCL2 
Overexpression of the anti-apoptotic gene BCL-2 and reduced expression of pro 
apoptotic gene BAX44 is seen in poorly differentiated cancers and in dysplastic 
epithelium adjacent to invasive lesions 
Mechanisms 
Tobacco                                Genetic instability 
Alcohol                                 Genetic mutations 
Viruses 
Betel nut 
 
Normal                 squamous                                   
Mucosal            cell   
Cell                 carcinoma 
 
Diet and                                  Loss of heterozygosity 
Dental factors                        Telomerase activation 
                                               DNA hypermethylation 
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FIELD CANCERISATION 
Separate primary tumours do not necessarily have to arise from different genetic 
mutational events but could have originated from a common clonal progenitor 
and then migrate to separate areas as described by Slaughter and colleagues.8 
SECOND PRIMARY TUMOUR 
Chronic exposure of the oral cavity to irritants results in the development of 
separate tumours in different anatomical sites. This can present synchronously 
(4%) within 6 months or metachronously (80%) delayed. Overall the risk of 
developing a second primary tumour is around 15%. 50% of metachronous 
tumours develop within two years.8 
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PATHOLOGY 
PREMALIGNANT LESIONS:  
This is a morphologically altered tissue in which there is an increased likelihood 
of developing cancer. 
LEUKOPLAKIA   
 This dermis given to a white keratotic patch or plaque which cannot be rubbed 
off and cannot be given any another diagnostic name39 (Fig.4). It arises because 
of chronic irritation of the local mucosa. Homogenous leukoplakia has low 
malignant potential but lesions with a speckled or verrucuous pattern, central 
erosion or ulcer, red patches or a peripheral nodule have a increased risk for 
malignancy; 4-18% of these lesions turn into invasive cancers.40 Alcohol, 
tobacco, chronic irritation due to ill fitting dentures, syphilitic glossitis, 
canididiasis, deficiency of vitamin A and B are considered to be risk factors for 
leukoplakia.41 
ERYHTROPLAKIA 
This appears as a red plaque and has a seven fold greater chance of malignant 
transformation than leukoplakia.42 They are most common over the tonsillar 
pillars and soft palate and do not arise from chronic irritation or inflammation. 
Mixed lesions in which leukoplakia and erythroplakia are seen together have a 
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five-fold increased risk than homogenous leukoplakia.43So it is wise to biopsy 
all erythroplakic lesions. 
LICHEN PLANUS 
This presents clinically with white lacy lines in the buccal mucosa against a 
violaceous background.                                         
PRE MALIGNANT CONDITIONS 
This includes states which are associated with a significantly increased risk for 
malignancy. 
DYSPLASIA 
This is a histological term which includes increased nuclear to cytoplasmic 
ratio, increased mitotic figures, pleomorphism, abnormal maturation of cells etc. 
Dysplasia can be mild-where changes are limited to the basal layers of the 
epithelium, moderate-involving two-thirds of the epithelium, severe-involving 
more than two thirds of the epithelium. Full thickness dysplasia is also known 
as carcinoma in situ. The risk of malignant transformation is 10-14%.44 
CHRONIC HYPERPLASTIC CANDIDIASIS 
This condition is due to candida albicans and produces dense plaques of white 
leukoplakia particularly around the commissures of the mouth. There is a high 
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incidence of malignant transformation especially in those who are 
immnunocompromised.8 
 
ORAL SUB MUCOSAL FIBROSIS 
Oral submucosal fibrosis is exclusive to Asians and is characterized by fibrous 
bands beneath the mucosa which limit mouth opening and tongue movement. 
(Fig.3) Histologically the epithelium is fibrosed, hyperplastic and may show 
dysplastic changes. This condition is associated with use of pan masala areca 
nut with or without concurrent alcohol use.8 
SIDEROPENIC DYSPHAGIA 
Sideropenia predisposes to cancer but causing epithelial atrophy which renders 
the mucosa more vulnerable to carcinogens. This is common in Scandinavian 
women.8 
SYPHILITIC GLOSSITIS 
By causing end arteritis syphilitic glossitis results in epithelial atrophy and more 
susceptibility to the effects of carcinogens. 
DYSKERATOSIS CONGENITA 
The syndrome complex of oral leukoplakia, nail dystrophy and reticular atrophy 
is called dyskeratosis congenita. 
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MALIGNANT LESIONS 
CLASSIFICATION OF TUMOURS 
1. Epithelial 
Squamous cell carcinoma  
Other variants of SCC 
Verrucous 
Spindle 
Lymphoepithelioma 
Undifferntiated 
Basaloid squamous cell carcinoma 
Adenocarcinoma 
Other variants of adenocarcinoma 
Malignant mixed carcinoma 
Adenocystic carcinoma 
Mucoepidermoid carcinoma 
Acinic cell carcinoma 
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2. Non-epithelial 
Melanoma 
Lymphoma 
Soft tissue sarcoma 
Plasmacytoma 
SQUAMOUS CELL CARCINOMA 
More than 90% of all oral cavity cancers are squamous cell carcinomas. 
Morphologically it can be: 
ULCERATIVE 
Ulcerative type is the most common and presents as oval or round ulcers with 
heaped up edges that bleeds easily and has the tendency to infiltrate deeply.  
EXOPHYTIC 
Exophytic tumours are less common have a superficial spreading pattern and 
also a better prognosis as.45 It is also the most common type arising from the lip. 
INFILTRATIVE 
Infiltrative tumours are aggressive, may exhibit perineural invasion, are 
common in the tongue and may invade the mandible. 
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BRODER’S GRADE46 
Histologic grading of squamous cell carcinoma into four grades is based on 
nuclear pleomorphism, extent of keratinisation, frequency of mitoses etc. The 
usefulness of Broder’s grading in predicting prognosis is unclear.47 
It is classified as 
a) Well differentiated (Grade – I >75% of keratin pearls) 
b) Moderately differentiated (Grade II 50-75% keratin pearls) 
c) Poorly differentiated (Grade III 25-50%of keratin pearls) 
d) Undifferentiated (Grade IV<25% of keratin pearls) 
VERRUCOUS CARCINOMA 
Verrucous carcinoma accounts for 5%48of oral malignancies. It is a variant of 
squamous cell carcinoma and clinically presents as an exophytic sharply 
circumscribed tumour with pushing borders that projects above the mucosal or 
cutaneous surface. They most commonly occur over the gingival and buccal 
mucosae and are more common in women [>78%] and the elderly. The 
histological appearance is that of a hyperplastic epithelium with intact basement 
membrane and no mitotic activity that classifies them as well- differentiated 
carcinoma. They generally have an indolent biologic course rarely ever 
metastasizing. The hybrid variety of verrucous carcinoma which has multiple 
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foci of squamous cell carcinoma is known to behave more aggressively with the 
ability to metastasize49and if treated with radiation, more likely to 
dedifferentiate into anaplastic carcinoma.49 
BASALOID SQUAMOUS CELL CARCINOMA 
This is yet another aggressive variant of squamous cell carcinoma which 
clinically presents as an ulcerative lesion. Microscopically it is characterised by 
basaloid cells that are arranged in the form of nest or cords interspersed with 
pseudoglandular spaces, a propensity to invade perineural spaces, high mitotic 
rate and a duplicated basal lamina.51 Among squamous cell carcinoma this has 
the highest recurrence rate. They also tend to metastasize more frequently and 
therefore a worse prognosis.52 
NON EPIDERMOID MALIGNANCIES 
They account for less than 10% of oral cavity malignancies and predominantly 
arise from the minor salivary glands. Other malignancies included in this group 
are melanoma, lymphoma, Kaposi’s sarcoma etc. 
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ADENOID CYSTIC CARCINOMA 
It is the most common (30-40%) malignancy arising from the minor salivary 
glands.53(Fig.5) They most commonly occur over the hard palate and are 
clinically characterized by local infiltration, perineural invasion in 5-73%54 and 
a slow growth rate. Distant metastases (50%) to lung, brain and bone are much 
more common than regional metastases(14%).55 Upto 15% of adenoid cystic 
carcinoma recur more than five years after diagnosis; recurrence is possible 
even after 15-20 years and therefore long term follow up is essential.56 High 
survival and low recurrence rates characterize adenoid cystic carcinoma of the 
oral cavity.57 
KAPOSI’S SARCOMA 
This is the most common malignancy associated with AIDS. Nearly 50% of 
AIDS associated Kaposi’s sarcoma has oral cavity involvement. These tumours 
are composed of endothelial cells with extravasated erythrocytes. Kaposi’s 
sarcoma most commonly involves the perioral skin, gingivae, hard palate and 
tongue. HHV-8 induced malignant degeneration is thought to be the reason for 
AIDS associated Kaposi’s sarcoma.  
MELANOMA 
Oral cavity melanomas are extremely rare58and are commonly found in the 
palate, gingivae, buccal mucosa and lip.59 Benign melanosis precedes melanoma 
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in around one-third of the cases.60Melanomas show positivity for S-100,HMB-
45.5895% melanoma of oral cavity are pigmented. Oral cavity melanomas have 
a poorer prognosis compared to cutaneous melanomas as they are frequently 
diagnosed late and also because the oral cavity has rich lymphatics and blood 
supply enabling easy dissemination of the tumour.  Long term follow up is 
absolutely essential because melanomas can recur as late as ten years after 
treatment. One should remember the possibility of metastatic melanomas which 
are frequently diagnosed late. 
LYMPHOMA 
Primary lymphomas of the oral cavity mostly arise from the waldeyer’s ring. 
While nearly 80% of patients with NHL have nodal involvement, 10% have 
extra nodal disease.62 Of these 2% can have oral cavity involvement63 involving 
the palate and the gingival most commonly.   
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CLINICAL PRESENTATION 
The most common symptoms are a non healing ulcer or a mass lesion in the 
mouth. Pain may or may not be associated. Other symptoms include. Pain-due 
to infection, ulceration or involvement of nerves, referred pain in ear is due to 
involvement of 9 and 10 cranial nerves and in cancers of tongue, due 
involvement of  lingual nerves where it is referred along the auriculotemporal 
nerve.  Persistent or bleeding ulcer. Loose teeth and ill fitting dentures-in 
cancers involving the alveolar ridge. Pain in the mandible. Trismus- when there 
is pterygoid muscles primarily seen in retro molar trigone cancers. Trismus is 
also considered to be a symptom of advanced disease. Numbness-indicates 
perineural invasion. Dysphagia- either due to posterior extension of the tumour 
or due to involvement of the geniohyoid muscle. Drooling of saliva- because of 
irritation of nerve fibres of taste and also due to difficulty in swallowing. 
Ankyloglossia (inability to protrude tongue)–due to involvement of tongue 
musculature. Odynophagia, Voice change- difficulty in articulation and 
restriction of tongue mobility is responsible for this symptom. Halitosis (foul 
smelling breath) due to infection and necrosis of the oral cavity. Facial nerve 
palsy-in advanced cases of buccal carcinoma. Cervical adenopathy-in advanced 
oral cavity cancers. Respiratory distress (rarely)-in terminally ill patients, 
systemic symptoms like malnutrition, dehydration, weight loss etc. 
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CANCER OF THE BUCCAL MUCOSA 
This is the most frequently involved site in Indians. The usual presentation is 
that of a lumpy sensation in the tongue; pain is rare but for the involvement of 
lingual and dental nerves. Early lesions are exophytic and can even penetrate the 
skin as they grow. Trismus, enlargement of the parotid gland due to duct 
obstruction etc can occur depending on the direction of extension of the tumour. 
CANCERS OF THE ORAL TONGUE 
The tongue is most commonly involved in the western population and second 
most commonly involved in Indians. These most commonly present with a mild 
irritation of the tongue and in later stages pain which radiates to the external 
auditory meatus. Speech and deglutition are affected when there is extensive 
infiltration of the tongue musculature. The ventral and the lateral aspects at the 
junction of the middle and posterior thirds of the tongue are most commonly 
affected.50 Lesions of the middle third may invade the floor of the mouth 
whereas lesions of the posterior third may grow behind the mylohyoid and 
present as a mass at the neck of the mandible. Rarely the hypoglossal nerve may 
be involved. 
 CANCER OF THE FLOOR OF MOUTH 
Early lesions appear as red ill defined areas with little induration; ulceration and 
rolled out edges become evident as the lesion enlarges. More than 90% of 
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lesions are found within 2 cm of the midline of the floor of mouth. While 
invasion to geniohyoid, genioglossus and the buccal mucosa is common the 
mylohoid acts as a strong barrier and is breached only when the lesion is 
advanced. Likewise late lesions may invade the mandible. The submandibular 
gland may be enlarged either due to tumour invasion or infection secondary to 
duct obstruction. 
CANCER OF THE LIP 
This may present as a discrete lesion most commonly in the vermilion border of 
the lip that is usually not tender until it ulcerates. In the United State, it is the 
second most commonly involve site.61The lower lip is more commonly affected 
(90%), commissure (<1%) and the upper lip (2-7%).64 Dermal lymphatic 
invasion is evident by erythema of skin and paraesthesia denotes perineural 
invasion. Advanced lesions invade the commissures, buccal mucosa, skin, wet 
mucosa of lip, adjacent mandible and finally the mental nerve. 
CARCINOMA OF THE GINGIVAE, HARD PALATE AND RETRO 
MOLAR TRIGONE 
These patients present with ill fitting dentures, loose teeth, non healing sores 
and paresthesia of the lower lip due to involvement of the inferior dental nerve. 
Cancers of the retromolar trigone present with pain referred to the external 
auditory meatus and trismus. 
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PATTERNS OF SPREAD 
DIRECT SPREAD 
Spread of oral cavity cancers is mainly determined by the local anatomy and 
therefore unique to each site. While muscle invasion is common, bone and 
cartilage acts as natural barriers to spread and tumours that come into contact 
with these structures are usually diverted along paths of least resistance. 
Tumours may extend into the parapharyngeal space and from there go either to 
the skull base or the neck. Luminal spread along ducts is also uncommon. 
Perineural invasion if present augur a poorer prognosis and also these tumours 
may track along a nerve to the skull base and then the central nervous system. 
Risk of distant metastases is increased if there is vascular invasion.   
LYMPHATIC SPREAD 
Risk of lymphatic spread is determined by size of the primary lesion, grade of 
the tumour, vascular space invasion, and density of capillary lymphatics. 
Squamous cell carcinoma is more likely to metastasize than sarcomas and minor 
salivary gland tumours. Lesions that are well lateralized spread to the ipsilateral 
nodes66 while lesions that are close to the midline, tongue base and may spread 
bilaterally. Contralateral nodal involvement may occur in well lateralized 
lesions if lymphatic pathways are blocked by surgery or radiotherapy. Most 
commonly, the level II nodes are involved. Usually anastomotic channels that 
cross the submental space provide a path for this spread. Around 16% of 
patients with squamous cell carcinoma had solitary metastases in level III and 
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IV without involvement of levels I and II. So called skip metastases68.The most 
important prognostic factor in squamous cell carcinoma is the presence of 
cervical nodes. Patients with a large, fixed node, involvement of multiple levels 
or extracapsular spread have an even poorer prognosis.69 
DISTANT METASTASES 
The most commonly involved distant sites are the lung (66%), bone (22%) and 
liver (9.5%).70Possibilities of distant metastases is dependent on N stage than T 
stage. Distant metastases are more likely if more than two nodes are involved 
and if there is extracapsular spread. 
 
TNM STAGING FOR ORAL CAVITY CARCINOMA5 
 
PRIMARY TUMOUR9 
 
• TX Unable to assess primary tumour 
• T0 No evidence of primary tumour 
• Tis Carcinoma in situ 
• T1 Tumour is < 2 cm in greatest dimension 
• T2 Tumour > 2 cm and < 4 cm in greatest dimension 
• T3 Tumour > 4 cm in greatest dimension 
• T4 (lip) Primary tumour invading cortical bone, inferior alveolar nerve, 
floor of mouth, or skin of face (e.g., nose or chin) 
• T4a  (oral) Tumour invades adjacent structures (e.g., cortical bone, into 
deep tongue musculature, maxillary sinus) or skin of face 
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• T4b (oral) Tumour invades masticator space, pterygoid plates, or skull 
base and/or encases the internal carotid artery 
NODE 
 
• NX  Cannot assess regional lymph nodes 
• N0  No evidence of regional lymph node metastasis 
• N1  Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest 
dimension 
• N2a Metastasis in a single ipsilateral lymph node, none > 3cm and < 6 cm 
in  greatest dimension         
• N2b Metastasis in multiple ipsilateral lymph nodes, none< 6 cm in 
greatest dimension 
• N2c Metastasis in bilateral or contralateral lymph nodes, all nodes < 6 cm 
in greatest dimension 
• N3 Metastasis in a lymph node > 6 cm in greatest dimension 
DISTANT METASTASES 
 
• MX Cannot assess for distant metastases 
• M0 No distant metastases 
• M1 Distant metastases 
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STAGE GROUPING: 
 
STAGE TUMOUR NODE METASTASIS 
STAGE 0 Tis N0 M0 
STAGE 1 T1 N0 M0 
STAGE 2 T2 N0 M0 
STAGE 3 T3 N0 M0 
 
T1-T3 N1 M0 
STAGE 4A T4a N0-N1 M0 
 
T1-T4a N2 M0 
STAGE 4B T4b Any N M0 
 
Any T N3 M0 
STAGE 4C Any T Any N M1 
 
ADVANTAGES CLINICAL STAGING: 
1) Designing treatment strategies2) Compare results3) Assess prognosis65 
DISADVANTAGES OF CLINICAL STAGING: 
While predicting prognosis it does not take into account certain important host 
factors which influence the outcome e.g. patient’s performance status,  
comorbidities, nutritional status, immune status.67Pathological features which 
influence prognosis like extracapsular speard, perineural invasion etc  are not 
included in the staging criteria. Other prognostic features like fixity of nodes, 
level of nodal disease etc are also not included. It relies heavily on clinical 
examination of the neck which is not infallible. The incidence of false negative 
physical examination (with occult metastases) varies from 16-60%.7 
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INVESTIGATIONS IN ORAL CAVITY MALIGNANCIES 
 
Evaluation of a patient with oral cavity malignancy should include 
1) History, 2) Physical examination, 3) Dental assessment, 4) Radiography, 5) 
Tissue biopsy, 6) Intraoperative visualization under general anaesthesia if 
needed. 
BIOPSY  
An incisional biopsy is taken from the ulcer under local anaesthesia. Specimen 
should include suspicious areas and normal mucosa avoiding necrotic areas. 
FINE NEEDLE ASPIRATION CYTOLOGY 
This is done for clinically palpable nodes. Ultrasonogram guided fine needle 
aspiration cytology is helpful in managing patients with non palpable neck 
nodes.  
CHEST X RAY 
Chest X ray gives useful information about metastases to the lung and second 
primary cancers if any. 
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ORTHOPANTOMOGRAM 
PANOREX-dental panoramic radiograph is useful for ruling out mandibular 
invasion but gives only limited information about the symphysis and lingual 
cortex. 
COMPUTED TOMOGRAM 
This is done for patients with trismus, lesions abutting the mandible, if marginal 
mandibulectomy is planned, in evaluating a N0 neck, to rule out carotid 
involvement, assessing the pterygoid region. 
MAGNETIC RESONANCE IMAGING 
Magnetic resonance imaging is superior to computed tomogram in picking up 
invasion of the base of the tongue, perineural invasion and is useful in people 
with dental amalgams which are visible in a computed tomogram scan as 
artefacts. Post-contrast magnetic resonance imaging is highly sensitive in 
detecting perineural invasion.72 
ULTRASONOGRAM 
Ultrasonogram can be used to screen non palpable lymphadenopathy with the 
added benefit of not exposing the patient to radiation. It can be combined with 
fine needle aspiration cytology and this has a specificity of around 90%.73 
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PET SCAN 
The precise role of a PET scan in oral malignancies is yet to be defined. At 
present it is used to detect nodal metastases and recurrent disease.74 
INDIRECT OR FIBREOPTIC LARYNGOSCOPY 
Is done to visualize posterior oral cavity. 
 DIRECT LARYNGOSCOPY OR OESOPHAGOSCOPY 
 Is required to know about the full extent of the disease, as well as to detect a 
second primary cancer, if any. 
 Maximum accuracy in diagnosing cervical metastases was with Ultrasonogram  
guided fine needle aspiration cytology (93%),followed by Magnetic resonance 
imaging (82%), Computed tomogram(78%), Ultrasonogram(75%), 
Palpation(69%). 
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TREATMENT OF ORAL CANCERS 
 
Choosing an initial treatment modality for oral cancers is one after taking into 
account: 
TUMOUR FACTORS: like size, site, location (anterior vs. posterior), 
proximity to bone (mandible or maxilla), cervical lymph node status, previous 
status, previous treatment, histology (type, grade and depth of invasion). 
PATIENT FACTORS: like age, general condition of the patient, tolerance, 
occupation, acceptance and compliance, life-style (smoking/drinking) and 
socio-economic considerations. 
PHYSICIAN FACTORS: like chemotherapy, radiotherapy, prosthetics, dental 
factors, rehabilitation services, support services.  
Ultimately THE GOAL: is to 1) cure cancer 2) preserve form and restore 
function 3) minimize adverse effects and delayed effects of treatment 4) prevent 
second primary tumours. 
TREATMENT OPTIONS: available for oral cavity cancers include surgery, 
radiotherapy, chemotherapy and a combination therapy.  
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PRINCIPLES OF SURGERY 
The mainstay of treatment of oral cancers is surgical excision. An adequate 
margin of 1-1.5 cm should be given to ensure proper resection. The resultant 
surgical defect is closed primarily or allowed to heal by secondary intention. 
Large defects are closed by split thickness skin graft, local rotational or 
advancement flap or a free flap.75 
Surgery and radiotherapy are equally effective in treating T1&T2 lesions. 
Therefore early lesions are preferentially treated by a single modality. Advanced 
lesions require combined modality treatment where radiotherapy is clubbed 
with surgery either preoperatively or postoperatively. The tumour factors 
determine the choice of surgical approach for a primary tumour.75 
ADVANTAGES OF SURGERY76 
• Lesser treatment time and also faster rehabilitation 
• Saves other modalities of treatment for second primary cancers 
• Provides a specimen that can be subjected to pathological examination for 
assessing adequacy of resection and also for deriving prognostic 
information. 
• Beneficial in patients with radiation induced complications 
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DISADVANTAGES OF SURGERY77 
• Risks associated with administering anaesthesia 
• Expensive 
• Functional disability post surgery  
TYPES OF SURGERY FOR PRIMARY CANCERS 
• Wide local excision 
• Composite oral resection 
• Composite oral resection with hemimandibulectomy 
• Maxillectomy 
• Hemiglossectomy 
MANDIBLE 
Mandible is involved due to77 
• Encroachment or abutting of bone 
• Direct invasion of bone 
• Prevention of surgical access  
BONY INVOLVEMENT 
• Even in the absence of radiographic findings, there is a high incidence of 
microscopic invasion of periosteum or the cortex by tumours that 
encroach the mandible. 
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•  Around 30% of tumours that encroach on the mandible have microscopic 
invasion and a normal looking mandible in conventional x rays and 
orthopantomograms. 
• Technetium-99 scans are more sensitive than radiographs but cannot 
differentiate between inflammation, infection and tumour. 
• A  highly precise multiplanar reformatting CT(dentascan) provides 
accurate  spatial information about destruction of cortex, inferior alveolar 
nerve and other structures.78 
• Direct invasion of the mandible apparent clinically or radiographically 
requires segmental mandibulectomy. 
TYPES OF MANDIBULAR RESECTION 
MARGINAL MANDIBULECTOMY  
This involves resection of inner or outer rim of the mandible preserving 
continuity of the mandible. It is done 1) for obtaining a satisfactory three 
dimensional margin around the primary tumour, 2) when the primary tumour 
approximates the mandible but is mobile, 3) if there is minimal cortical erosion 
of the mandible. Marginal mandibulectomy is contraindicated 1) if there is 
invasion into cancellous part of the mandible, 2) extensive soft tissue disease, 3) 
pipe stem mandible, 4) previously irradiated edentulous mandible. 
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SEGMENTAL MANDIBULECTOMY 
This involves removal of bone from the angle to the mental foramen. 
Indications are 1) cancellous bone involvement, invasion of lingual or lateral 
cortex of the mandible. 
PARTIAL MANIBULECTOMY 
This involves removing a part of mandible from the mental foramen to the 
coronoid process line removing the coronoid process but sparing the condyle of 
the mandible.  
HEMIMANDIBULECTOMY 
Here bone from the symphysis to the condyle on one side is removed. 
MANDIBULAR RECONSTRUCTION8 
Functional impairment of speech and deglutition following segmental resection 
varies with the location of the bony defect. Even a small anterior resection 
causes significant impairment compared to lateral defects and necessitates the 
use of reconstructive techniques. 
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METHOD OF RECONSTRUCTION 
 
SURGICAL ACCESS 
Different approaches to improve access are77 
1) MANDIBULAR SWING APPROACH / MANDIBULAR 
OSTEOTOMY 
This requires a midline lip splitting incision to expose the symphysis. 
Mandibular osteotomy can then be done either in the midline or a paramedian 
position and mylohyoid muscle is then divided enabling the mandible to swing. 
The disadvantages are lip scarring, mandibular malunion, loss of teeth and 
paresthesia. 
METHOD TECHNIQUE 
 
No reconstruction Primary closure 
Soft tissue only Pectoralis major myocutaneous flap 
 
Alloplastic material 2-4 mm reconstruction plate alone 
Combination alloplastic/soft Tissue 2-4 mm reconstruction plate, PMMCF 
Non-vascularized bone grafts Titanium tray and cancellous chips 
Vascularised bone graft Fibula (edentulous and dentate) Iliac 
crest(dentate) scapula concomitant   
soft  tissue defect 
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2) VISOR-FLAP APPROACH 
The mandible is kept intact and skin, soft tissues are dissected off it and lifted 
superiorly granting access to the anterior and lateral oral cavity. This approach 
may compromise the blood supply to the mandible and cause damage to the 
mental nerves. 
3) TRANSORAL / INTRAORAL APPROACH:  
Useful for small cancers in the oral cavity. 
4) CHEEK-FLAP APPROACH (PATTERSON OPERATION) 
 
5) LIP SPLIT INCISION 
 
RECONSTRUCTIVE SURGERY9 
Primary reconstruction of surgical defects with well vascularised flaps allows 
for prompt healing, an early return to normal function, and a shorter hospital 
stay. 
As a rule reconstruction of the post excisional defect is to be done in the same 
sitting, save for those cases where there is ambiguity about the adequacy of 
resection and general condition of patient is poor extensive surgery is ruled out. 
POST-EXCISIONAL DEFECTS MAY BE COVERED BY75  
• Primary closure  
• Split skin graft 
• Local graft 
• Skin and other tissues brought from a distant site 
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• Free flap micro vascular anastomosis 
SPLIT SKIN GRAFT 
This is excellent procedure in those places where the bed is suitable. These 
grafts cannot fill a cavity or cover an exposed bone and are contraindicated in 
an irradiated bed. Graft contraction is another undesirable quality of these 
grafts. The whitish appearance of these grafts is due to desquamation. 
FULL THICKNESS GRAFT 
These grafts do not contract and therefore achieve better cosmesis. 
The donor site should be hairless for obvious reasons. 
MUCOUS MEMBRANE GRAFT 
These are the ideal free grafts but availability is limited. 
LOCAL FLAPS 
These are readily available and versatile flaps. Some examples are 
• Forehead flap 
• M. Narayanan bipolar flaps 
• Sternomastoid myocutaneous flap 
• Trapezius flap 
• Platysma myocutaneous flap 
• Tongue flaps 
• Temporalis flap 
• Naso labial flap 
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• Estlander rotating flap 
• Fries’ modified Bernard facial flap 
• Gillies fan flap 
• W flap plasty 
• Abbe flap 
• Karapandzic flap 
• Johansen step ladder flap 
REGIONAL ARTERIALIZED FLAPS 
These flaps have a good blood supply and obviate the need for microvascular 
anastomosis. Some examples are 
• Deltopectoral flap 
• Latissmus myocutaneous flap 
• Pectoralis major myocutaneous flap 
• Rectus abdominis flap 
FREE FLAPS 
 These flaps are composite sections of tissue with microvascular anastomosis 
and provide excellent cosmesis and functional benefit. 
• Free osteocutaneous groin flap 
• Radial forearm flap (Chinese flap) 
• Osteocutaneous fibular graft 
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PRIMARY RECONSTRUCTIVE OPTIONS8 
ANATOMICAL 
SITE 
 
MICROVASCULAR FREE 
FLAP 
 
ALTERNATE FLAP 
 
Floor of Mouth Forearm B/L nasolabial folds 
Lateral tongue Forearm Platysma skin flap 
Total Glossectomy Rectus abdominis Pectoralis major 
Buccal mucosa Forearm Temporalis muscle 
Low Hard palate Temporalis muscle Forearm 
High Iliac crest Fibula 
 
MICROVASCULAR FREE FLAPS8  
FLAP BLOOD SUPPLY VARIANTS 
Forearm Radial artery skin only; fascia only 
Composite forearm Radial artery skin and bone(radius) 
Anterolateral thigh Perforators of Profunda 
femoris 
skin only; skin& muscle 
Rectus abdominis Deep inferior epigastric 
artery 
skin and muscle; muscle 
only 
Fibula Peroneal artery Bone and skin; bone; 
fascia 
Ilium Deep circumflex iliac                                       
artery 
Bone; bone&muscle, 
bone, muscle&skin. 
Scapula Subscapular artery Bone and skin; bone and 
muscle. 
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NECK DISSECTION 
Metastases to the neck decrease survival by around 50%. Neck metastases are 
effectively treated by a single modality if a single node is involved and there is 
no extracapsular spread. More advanced disease requires a combined 
approach.75 
CLASSIFICATION OF NECK DISSECTION: 
RADICAL NECK DISSECTION 
Radical neck dissection was first described by Crile in 1906.79 It is a bloc 
removal of fat, fascia, lymph nodes, level I-V nodes along with 
sternocleidomastoid and omohyoid, internal  jugular vein, spinal accessory 
nerve,cervical plexus, submandibular salivary gland and tail of parotid, 
prevertebral fascia. This is appropriate for N2, N3 lesions. This is an operation 
with high morbidity. Patients experience chronic shoulder pain, numbness, 
restriction of movement, fibrosis and cosmetic deformity. 
MODIFIED RADICAL NECK DISSECTION  
This was described by Bocca. Modified radical neck dissection spares some or 
all of the non-lymphatic structures in the neck and causes less morbidity when 
compared to Radical neck dissection.75Suited for N0 neck, nodes of size 1-3 cm 
and mobile, for removal of residual N2, N3 disease postradiotherapy.76There are 
three types: 
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Type-1 preserves the spinal accessory nerve 
Type-2 preserves the internal jugular vein in addition to the spinal accessory 
Type-3 preserves the sternocledomastoid in addition to the above structures. 
SELECTIVE NECK DISSECTION77 
This dissection preserves certain lymph node groups. 
Supraomohyoid neck dissection – only level I - III nodes are removed. 
Extended supraomohyoid neck dissection- levels I – IV are removed 
Posterolateral neck dissection – removal of II - V groups 
Lateral neck dissection- removal of II - IV nodes 
Anterior compartment dissection- removal of level VI nodes only 
EXTENDED RADICAL NECK DISSECTION 
In addition to structures removed in Radical neck dissection, this surgery 
removes parapharyngeal and superior mediastinal nodes and non lymphatic 
structures like the carotid artery, hypoglossal nerve, vagus nerve and paraspinal 
muscles. 
INCISIONS USED FOR NECK DISSECTION 
Mac fee incision, Crile incision, Martin incision, Schechter incision. 
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COMPLICATIONS OF NECK DISSECTION8 
Bleeding, pneumothorax, raised intracranial pressure, wound breakdown, 
infection, necrosis of skin flap, seroma, carotid rupture, chylous fistula, frozen 
shoulder. 
MANAGEMENT OF NECK8 
CLINICALLY NODE NEGATIVE NECK 
ELECTIVE NECK DISSECTION  
Incidence of occult metastases to neck nodes is 30%, particularly in patients 
with cancer of the tongue and floor of mouth and these cancers managed by 
supraomohyoid neck dissection. It is advisable to do extended supraomohyoid 
neck dissection for carcinoma tongue to cover skip metastases. 
ELECTIVE NECK IRRADIATON 
When the primary tumour is treated with surgery irradiation is given to the 
neck. 
CLINICALLY NODE POSITIVE NECK 
N1 DISEASE: 
Managed by selective supraomohyoid neck dissection. 
N2A AND N2B DISEASE: 
Managed by radical or modified radical neck dissection followed by post-
operative radiotherapy. Palliative radiotherapy is given to unfit patients. 
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N2C DISEASE 
Requires bilateral neck dissection and preservation of internal jugular vein on  
the minimally involved side followed by postoperative radiotherapy. 
N3 DISEASE  
If the disease is resectable radical neck dissection is done followed by 
radiotherapy and if it is not, radiotherapy is given first to make it resectable and 
radical neck dissection is done. 
 COMPLICATIONS OFSURGERY 
• Oral incompetence 
• Facial disfigurement 
• Flap necrosis 
• Orocutaneous fistula 
• Loss of dentition 
• Salivary gland obstruction secondary to duct disruption 
• Nerve injuries and associated morbidities- facial, hypoglossal 
and lingual nerves 
• Dysphagia 
• Microstomia  
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PRINCIPLES OF RADIOTHERAPY 
Radiotherapy is suited for Squamous cell carcinoma which are vascularised and 
well oxygenated and hence, more radiosensitive. Advanced lesions which 
invade bone or the muscle are relatively more radioresistant.77 
For early lesions surgery and radiotherapy both are equally effective. For 
advanced lesions radiotherapy is and useful adjunct preoperatively and 
postoperatively in controlling locoregional disease.75The usual dose given varies 
from 65-75 Gy. Radiotherapy failures are managed by surgery. 
ADVANTAGES OF RADIATION OVER SURGERY76 
• Retains tissues thereby preserving function and appearance 
• Avoids post operative complications 
• Morbidity is minimal when compared to surgery 
• Permits surgery to be used as a salvage procedure. 
MODE OF RADIATION77 
• EBRT- external beam radiation. 
•  Hyperfractionation entail giving smaller twice daily doses and this has 
been shown to increase loco regional control54 
•  Three dimensional conformal radiotherapy minimises exposure to 
normal tissues. 
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• IMRT – intensity modulated radiation. Uses computer technology and 
sleeves to block normal tissue and permits maximum dose to be given to 
the tumour and minimizes exposure to important structures. 
• Interstitial radiotherapy-brachytherapy. This technique is given in 
conjunction with EBRT, it enables a large dose to be given to the target 
tissue while minimising the dose given through EBRT thereby 
eliminating unwanted effects like trismus, xerostomia. But it requires 
administration of general anaesthesia to place catheters and elective 
tracheostomy should be performed to safeguard against potential airway 
compromise. 
• Intraoral orthovoltage or electron cone radiotherapy minimises exposure 
to the mandible in particular.  
PREOPERATIVE RADIOTHERAPY  
INDICATIONS76 
• Fixed nodes 
• When gastric pull up is used for reconstruction 
• Open biopsy of a positive neck node 
• If post operative RT will be delayed > 8 weeks 
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ADVANTAGES OF PREOPERATIVE RADIOTHERAPY77 
• Converts an inoperable lesion to an operable one 
• Extent of surgery 
•  Decreases the number of distant metastasis  
DISADVANTAGES OF PREOPERATIVE RADIOTHERAPY77 
• Wound healing problems 
• Difficulty in assessing tumour margin during surgery 
POSTOPERATIVE RADIOTHERAPY 
INDICATIONS75 
• Margins <  5 mm 
• Extracapsular extension 
• Multiple positive nodes 
• Soft tissue invasion 
• Endothelial lined space invasion 
• Perineural invasion 
• Locally aggressive poorly differentiated tumour 
• Tumour spillage during resection 
• Advanced stage 
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ADVANTAGE OF POSTOPERATIVE RADIOTHERAPY76 
• Margins are better delineated 
• A  higher dose of RT can be safely used 
• Healing is better 
• Decreases operative morbidity 
DISADVANTAGES OF POSTOPERATIVE RADIOTHERAPY76 
• Distant metastases are more likely to be higher 
• Vascularity is likely to be reduced post surgery 
• Delay in starting RT could cause progression of the disease 
• A larger dose in necessary to cover surgical dissection 
RADIOTHERAPY IS ALSO INDICATED FOR77 
• T1 and T2 tumours radiotherapy is as useful as surgery 
• Relapsing tumours  
• As palliation 
• Electively for neck nodes 
COMPLICATIONS OF RADIOTHERAPY8 
• Xerostomia 
• Mucositis 
• Dysguesia 
• Osteoradionecrosis 
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• Trismus 
• Dysphagia 
• Thyroid  dysfunction 
• Atherosclerosis of carotid 
• Visual impairment 
• Radiation neuritis 
 
 
 
 
 
 
 
 
 
 
 
 
65 
 
PRINCIPLES OF CHEMOTHERAPY 
• Insufficient if used as a single modality as it is not curative. 
• Used in combined modality treatment, especially in patients with 
advanced disease (stage III and IV). Chemotherapy also enhances the 
effects of radiotherapy. 
INDICATIONS FOR CHEMOTHERAPY 
• To prevent the development of second primary tumours 
• As palliation in patients with incurable, recurrent and metastatic disease  
• To improve the chances of cure 
• For organ preservation80 
ADVANTAGES OF CHEMOTHERAPY 
• Statistical improvement in disease free survival rate81 
• Concurrent chemoradiation results in improved locoregional control and a 
decrease in the number of distant metastases. 
• Chemotherapy may also act as a radiosensitizer. 
DISADVANTAGES OF CHEMOTHERAPY 
• There is no increase in the overall survival rate.82 
• Toxic side effects of chemotherapeutic drugs like mucositis, neutropenia 
etc which is seen in around  12-50% of patients.83 
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INDUCTION CHEMOTHERAPY: 
Chemotherapy is given prior to surgery, radiation or chemoradiation in an effort 
to improve locoregional control and decrease the possibility of distant 
metastases.84 
Induction therapy with a triplet of cisplatin, 5-FU and taxane produced a better 
response. Presently the role of induction therapy is unclear.76 
CONCURRENT CHEMOTHERAPY: 
Here chemotherapy is given simultaneously with radiation. There are three main 
approaches for concurrent chemotherapy.85 
1) Single agent or combination chemotherapy with a continuous course of 
radiotherapy 2) combination chemotherapy with a split-course radiotherapy 
3) Chemotherapy alternating with radiotherapy 
A variety of drugs and combinations have been used but according to NCCN 
guidelines concurrent cisplatin with radiotherapy should be the preferred 
choice.86 
ADJUVANT CHEMOTHERAPY: 
Here chemotherapy is given after surgery. Overall survival may not be 
improved but the incidence of distant metastases appears to be decreased. 
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Chemotherapy may be given as a single agent or as and combination which is 
arguably more effective than a single agent. 
DRUGS USED AND THEIR DOSAGE 
 Methotrexate  
Standard dosing is 40 mg/m2 IV weekly. Based on toxicity dose should be 
decreased or can be increased upto 60 mg/m2 
Cisplatin 
Standard dosing is 75-100mg/m2 IV every 3 – 4 weeks 
Carboplatin 
More commonly used as its adverse effects are less compared to cisplatin. 
Taxanes 
Paclitaxel should be given along with growth factor support at a dose of 250 
mg/m2 IV over 24 hours. 
Docetaxel is given at a rate of 60-100 mg/m2 over an hour. It has fewer side 
effects when compared to paclitaxel. 
5- Fluorouracil 
Standard dose is 1000mg/m2 IV over 3 – 5 days and repeated in 28 day cycles. 
Cituximab 
This is a chimeric immunoglobulin G antibody that binds to EGFR which is 
highly expressed in head and neck cancers.87 
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RECOMMENDATION 
The best way of cure is by prevention. Screening of high risk group should be 
done. 
It was evident that most of our patients and by extrapolation the general public 
have a very poor understanding of dental hygiene and oral pathologies. Patients 
fail to recognize the early signs of oral malignancy and even if they do, choose 
to stay away from health care due to fear that there might be something wrong 
and consequently present late. The adverse effects of treatment put off patients 
from pursuing treatment. 
Hence it is apparent that the need of the hour is to go into the villages and 
educate people about the early symptoms and signs of malignancy, the 
importance and the need of regular oral check up, the ill effects of habits that 
predispose to the development of oral premalignancy and malignancy and the 
need to avoid them. Our college conducts awareness programs on oral cancers 
in the local villages, which will help towards furthering that goal.Health 
education through mass media and posters in Health centers should be 
undertaken. Education of youth by mass media with a ban on advertisement of 
Tobacco, Alcohol is the need of the hour. 
Dental surgeons and general practitioners should assume a bigger role and 
detect oral lesions when they are still operable and promptly refer patients to 
higher centers for proper management.All health professionals should be 
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educated about ways to detect oral carcinomas in their early stages and refer 
them to appropriate centres. 
Regional and district hospitals should have the capability to carry out 
histological diagnosis. 
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MATERIALS AND METHODS 
 
This study includes all patients who reported to the departments of surgery, 
medical oncology, radiation oncology and surgical oncology at Govt. Rajaji 
Hospital who were diagnosed with oral cancer. The study was for a period of 
Twenty four months from Jan 2011 to Dec 2012. There was no specific 
selection criteria used to select cases; patients came to the departments either 
directly or were referred from other departments and other hospitals after 
malignancy was proven by histopathological examination. Diagnosis was 
confirmed by histopathological examination of specimen which was obtained 
by wedge biopsy of the ulcer/growth. Detailed history regarding number, 
duration of symptoms, habits like smoking, tobacco / pan chewing were 
obtained, baseline investigations like a complete hemogram, blood 
biochemistry, X-ray chest and X-ray mandible were done as required. 
It was followed by a through physical examination to accurately assess the size, 
extent and infiltration of tumour and neck nodes.  All patients were given TNM 
staging. Patients with advanced disease were given chemoradiotherapy except 
in rare instances where surgery was done following chemoradiotherapy for 
residual disease. Those patients with inoperable disease were treated with 
palliative radiotherapy. Radiotherapy was given as external beam radio therapy 
using radioactive cobalt- 60, as the definitive treatment for advanced stages                          
(stage 3 and 4) at a dose of 66 Gy (2.0 Gy/day for 5 days/week for a total of 6 
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weeks in 28-35 sittings)  for primary and 50 Gy (2.0 Gy/day for 5 days/week for 
a total of 6 weeks) for neck combined with cisplatin at a dose of 100 mg/ m2, 5-
FU at 1000 mg/m2 as infusion on  1,22nd and 43rd days as a chemoradiotherapy. 
Patients with early & operable disease was treated with surgery depends on site. 
Primary  reconstructions of the post excisional defect was done for all patients 
which included Primary suturing, Split skin graft, Pectoralis major 
myocutaneous flap, Pectoralis major osseomyocutoneus flap and Fore head flap. 
Pectoralis major myocutaneous flap was used in majority of cases for both inner 
lining and cover. 
 
RESPONSE CRITERIA  
An excellent response meant a complete regression of tumour and nodes while 
persistence of residual lesion after chemoradiotherapy was considered partial 
response and residual lesion was treated with surgery. 
 
FOLLOW UP 
Patients whose lesions completely regressed were followed up with observation. 
Patients with residual lesion underwent salvage surgery to resect residual 
tumour along with a RND. All patients were followed up two weeks after 
surgery and follow up was done monthly for the 1st year and once in 3 months 
for the 2nd year during. Recurrences were managed with chemoradiotherapy.  
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LIMITATIONS OF THE STUDY  
 
1. The study was plagued with a very high dropout rate even at the initial stages 
of the study, as some patients were not willing for surgical procedure. 
2. Data regarding tumour free interval, survival period, recurrence rate etc were 
not available. This can be attributed to the short follow up period. 
3. Since most of the patients presented with advanced disease, proper evaluation 
of primary radiotherapy in early stage of disease could not be studied. 
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OBSERVATION AND ANALYSIS 
This study is based on 162 patients admitted in the departments of surgery, 
surgical, radiation and medical oncology of GRH, Madurai for a period of two 
years from Jan 2011 to Dec 2012.  
TABLE-1 
DISTRIBUTION OF PATIENTS ACCORDING TO AGE AND SEX 
 
AGE 
MALE FEMALE TOTAL  
NO % NO % NO % 
21-30 1 0.62 3 1.85 4 2.47 
31-40 9 5.56 7 4.32 16 9.88 
41-50 16 9.88 11 6.79 27 16.67 
51-60 32 19.75 19 11.73 51 31.48 
61-70 29 17.90 20 12.35 49 30.25 
>71 13 8.02 2 1.23 15 9.25 
Total 100 61.73 62 38.27 162 100% 
 
The maximum number of cases 19.75% (32 cases) studied in males was in the 
51-60 age groups. In females the maximum numbers of cases were seen in the 
61-70 age group 12.35 %( 20 cases). Overall, in both males and females the 
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maximum number of cases was noted in the 6th and 7th decade 31.48 (51 cases) 
and 30.25(49 cases) respectively. (Dia.1&2) 
TABLE-2 
DISTRIBUTION OF PATIENTS ACCORDING TO SEX 
Age 
 
21-30 
 
31-40 41-50 51-60 61-70 >71 Total 
Male 1 9 16 32 29 13 100 
Female 3 7 11 19 20 2 62 
M:F 1.00:3 1.29:1 1.45:1 1.68:1 1.45:1 6.5:1 1.61:1 
 
Males constituted 61.73% (100 cases) of the cases where as females made up 
the remaining 38.27 %( 62 cases). The sex ratio obtained in the study was 
1.61:1 with a range varying from 1:3 to 6.5:1. Except for the third decade all 
other decades showed a male predominance. (Dia.3)  
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TABLE-3 
DISTRIBUTION OF PATIENTS ACCORDING TO SITE  
 
RMT= Retro molar trigone, FOM= Floor of mouth, HP=Hard palate 
The study revealed that the buccal mucosa was most commonly involved in 
both the sexes 36.42 %( 59 cases) followed by the tongue 35.18 %( 57 cases), 
alveolus, hard palate, lip, floor of mouth and retromolar trigone. 
In males tongue 24.69 %( 40 cases) followed by buccal mucosa 22.22 %( 36 
cases), hard palate, alveolus, lip, floor of mouth and retromolar trigone were 
most commonly involved. 
SITE 
 
MALE % FEMA
LE 
% TOTAL % 
BM 
 
36 22.22 23 14.20 59 36.42 
Tongue 
 
40 24.69 17 10.49 57 35.18 
Alveolus 
 
6 3.70 10 6.17 16 9.87 
HP 
 
11 6.79 3 1.85 14 8.64 
LIP 
 
4 2.47 7 4.32 11 6.79 
RMT 
 
1 0.62 - - 1 0.62 
FOM 
 
2 1.24 2 1.24 4 2.48 
 
TOTAL 100 61.73 62 38.27 162 100 
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In females buccal mucosa was the most frequently involved site14.20 %( 23 
cases). Tongue was the second most commonly involved site 10.49 %( 17 
cases) followed by alveolus, lip, hard palate and floor of mouth in that order. No 
case involving the retromolar trigone was reported in females. (Dia.4) 
TABLE-4 
DISTRIBUTION OF PATIENTS BASED ON THEIR HABITS 
  Habit   Male    %    Female     %    Total    % 
BT 25 15.43 52 32.10 77 47.53 
SA 17 10.49 - - 17 10.49 
BTSA 12 7.41 - - 12 7.41 
BTS 10 6.17 - - 10 6.17 
BTA 7 4.32 - - 7 4.32 
BS 7 4.32 - - 7 4.32 
BSA 6 3.70 - - 6 3.70 
BA 6 3.70 - - 6 3.70 
S 6 3.70 - - 6 3.70 
NO RISK 4 2.48 10 6.18 14 8.66 
 
B=betel nut, S=smoking, T=tobacco, A=alcohol. 
The habit that was most prevalent among both males and females was quid 
chewing; seen in 47.53% (77 cases). In males quid chewing 15.43% (25 cases) 
followed by smoking combined with alcohol consumption10.49% (17 cases) 
and quid chewing with smoking and alcohol 7.41% (12 cases) were noted. In 
females the most common habit was chewing quid seen in 32.10% (52 cases). 
Around 6.18% (10 cases) of females had no identifiable risk factors. (Dia.5) 
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TABLE-5 
DIFFERENT MODES OF PRESENTATION 
CF BM 
TON
GUE 
LIP 
ALVE
OLUS 
H
P 
FO
M 
RMT % 
 
TOT
AL 
ULCER 55 57 8 16 10 4 1 93 151 
SWELLIN
G 
25 17 8 9 8 2 - 42.6 69 
PAIN 1 10 - 2 6 3 3 15.43 25 
TRISMUS 5 - - 2 - - 2 11.73 9 
RMT EXT 8 - - 3 - - 2 8.02 13 
OCF 5 - - - - - - 3.09 5 
ES 20 20 - - - - - 24.7 40 
DC 12  - - - - - 7.40 12 
DYSPHA
GIA 
- 7 - - - - - 4.32 7 
AG - 10 - - - - - 6.17 10 
LUMP 
NECK 
- 4 - - - - - 2.47 4 
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CF=clinical features, BM=buccal mucosa, ES=excessive salivation, 
DC=difficulty in chewing, AG= ankyloglossia. 
The most common symptom was an ulcer in the mouth 93% (151 cases). 
Swelling in the oral cavity was the next most common symptom seen in 42.6% 
(69 cases). Excessive salivation was the third most common symptom seen in 
24.7% (40 cases). Pain was seen in 15.43% (25 cases) and was the next major 
presenting feature. Just 2.47% (4 cases) presented with a lump in the neck. 
(Dia.6) 
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TABLE-6 
ASSOCIATION OF VARIOUS PREMALIGNANT LESIONS 
 
The most common premalignant condition encountered in the study was 
leukoplakia 33.95% (55 cases). Around 30.86% (50 cases) in the study had no 
identifiable premalignant condition. (Dia.7) 
 
 
 
 
S.NO PRE-MALIGNANTLESION TOTAL % 
1 Candidiasis 7 4.32 
2 Erythroplakia 21 12.96 
3 Sub mucosal fibrosis 14 8.64 
4 Leukoplakia 55 33.95 
5 Erythroleukoplakia 8 4.95 
6 Submucosalfibrosis+erythroleukoplakia 6 3.70 
7 No association 50 30.86 
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TABLE-7 
CORRELATION BETWEEN SITE OF OCCURENCE AND CLINICAL 
PATTERN 
 
     Site 
Ulcerative Proliferative Ulceroproliferative 
Total 
No % No % No % 
BM 35 21.6 4 2.47 20 12.35 59 
Tongue 40 24.69 - - 17 10.49 57 
FOM 2 1.23 - - 2 1.23 4 
Alveolus 7 4.32 - - 9 5.55 16 
RMT 1 0.63 - - - - 1 
LIP 3 1.85 3 1.85 5 3.09 11 
HP 6 3.70 2 1.23 6 3.70 14 
Total 94 58.03 9 5.55 59 36.42 162 
 
Overall ulcerative pattern of growth was found to be the most common in the 
study 58.03% (94 cases). Ulceroproliferative pattern was the second most 
common 36.42 %( 59 cases) and proliferative pattern of growth was the least 
common accounting for 5.55% (9 cases). Ulcerative lesions were most common 
in the tongue 24.69% (40 cases) followed by the cheek 21.6% (35 cases), FOM, 
alveolus, HP, lip and RMT. Ulceroproliferative lesions were more prevalent in 
the cheek 12.35% (20 cases) followed by the tongue, alveolus, lip, HP and FOM 
( DIA-8). 
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TABLE-8 
DISTRIBUTION ACCORDING TO VARIOUS HISTOLOGICAL TYPES                
S.NO TYPE NO NO & % % 
1 SCC-grade I 72 
 
 
152(93.83%) 
44.44 
2 SCC-grade II 56 34.57 
3 SCC-grade III 24 14.81 
4 Verrucous carcinoma 5  3.70 
5 Melanoma 1  0.62 
6 Adenoid 
Cystic carcinoma 
3  1.85 
 
Squamous cell carcinoma was the most common histological type and 
accounted for 93.83% (152 cases). Grade I SCC accounted for 44.44% (72 
cases) and grade II accounted for 34.56 (56 cases). Grade III was the least 
common an accounted for 14.81% (24 cases). Verrucous carcinoma was the 
second most common histological type followed by melanoma and adenoid 
cystic carcinoma. (Dia.9) 
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TABLE-9 
STAGE WISE DISTRIBUTION OF PATIENTS 
S.NO STAGE NO % 
1 I 8 4.93 
2 II 23 14.20 
3 III 52 32.10 
4 IV 79 48.76 
In the study most patients presented in stage-IV, 48.76% (79 cases). Stage- III 
patients were second most common 32.10% (52 cases). Thus most patients 
presented late as stage III and stage IV. Stage I and II patients were 
comparatively less. (Dia.10) 
TABLE-10 
DISTRIBUTION OF PATIENTS ACCORDING TO SOCIOECONOMIC 
STATUS 
S E STATUS NO % 
LOW 161 99.38 
MIDDLE 1 00.62 
UPPER - - 
 
Majority of the patients were overwhelmingly from a low socioeconomic 
stratum 99.38% (161 cases) (Dia-11). 
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TABLE-11 
DISTRIBUTION OF PATIENTS ACCORDING TO   PRIMARY LESION 
& NODAL STATUS 
PRIMARY LESION NODAL STATUS METASTASIS 
T N0 % N N0 % M N0 
T0 - - N0 28 14.20 M0 162 
T1 12 4.32 N1 55 29.63 M1 - 
T2 39 19.14 N2a 12 14.81   
T3 43 26.54 N2b 50 30.86   
T4 68 50 N2c 13 8.02   
   N3 4 2.47   
 
In the study most patients presented with advanced lesion T4 (68 cases) N2 (75 
cases). The number of patients who presented with T3 lesion was (43 cases); the 
proportion of T2 and T1 cases was less. Most of the cases presented with N2 
nodal disease (75 cases). The proportion of cases with N1disease was (55 
cases).Cases with N3 disease was very low (4 cases). There were no cases with 
distant metastases (Dia -12,13,14). 
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TABLE-12 
NUMBER OF PATIENTS OPERATED BASED ON STAGE 
STAGE NUMBERS 
I 8 
II 23 
III 14 
IV 19 
 
31 cases with stage I & II disease and 33 cases with stage III & IV had 
surgery.(Dia.10) 
TABLE- 13 
NUMBER OF PATIENTS OPERATED BASED ON SITE AND 
HISTOLOGY 
Type BM Tongue HP Alveolus Lip Total 
SCC 18 22 - 2 1 43 
Salvage-SCC 4 3 - 3 2 12 
ACC - - 2 - 1 3 
Verrucous 4 - - - 2 6 
Total 26 25 2 5 6 64 
 
85 
 
Of the total 64 patients who had surgery, 43 patients were offered surgery as the 
primary treatment. 12 patients had surgery following  chemoradiation. 3 patients 
with ACC and 6 patients with verrucous carcinoma had surgery. Most of the 
patients with oral cavity cancers who reported at late stages opted for non-
operative treatment. Overall 39.51% of patients with oral cavity cancers 
underwent surgery. (Dia.15&16) 
TABLE-14 
 PATIENTS WHO UNDERWENT SURGERY FOR VERUCCOUS 
CARCINOMA   
Surgery Site No Recurrence Defaulter Death 
WLE,DPF BM 1 - - - 
WLE,FHF BM 2 - - - 
WLE,NLF BM 1 - - - 
WLE,FHF Lower lip 1 - - - 
WLF.ERF Lower lip 1 - - - 
Total BM-3,Lip-2 6 - - - 
 
No recurrences were reported among the six patients who were operated for 
veruccous carcinoma. (Fig.6, 7, 8, 9&10) 
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TABLE-15 
PATIENTS WHO HAD SURGERY FOR ACC WHO DEVELOPED 
RECURRENCE           
Surgery Site No Recurrence Defaulter 
WLE Hard palate 2 - 1 
WLE,AF,FHF Upper lip 1 - - 
Total HP-2,Lip-1 3 - 1 
 
There were no recurrences in the 3 patients with ACC who had surgery. One 
patient defaulted. 
TABLE-16 
BUCCAL MUCOSA STATISTICS 
 
Procedure No Post RT Post CRT Recurrence Defaulter Death 
WLE 1 - - 1 - - 
WLE,DPF 1 - - - - - 
WLE,FHF 8 - - - - - 
WLE,SOHND,
FHF 
6 6 - - 1 
- 
WLE,DPF, 
RND 
1 - 1 1 - 
- 
WLE,HM, 
PMMCF,RND 
1 - 1 1 - 
 
- 
Total 18 6 2 3 1 - 
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LIP STATISTICS 
Procedure No Post RT Post CRT Recurrence Defaulter Death 
WLE,FHF 1 - - - - - 
Total 1 - - - - - 
 
ALVEOLUS STATISTICS 
 
TONGUE STATISTICS 
Procedure No Post RT Post CRT Recurrence Death 
HG,RND 9 - 8 1 - 
HG,SOHND 7 7 - 1 - 
HG,ESOHND 1 1 - - - 
WLE,SOHND 4 4 - 1 - 
HG,HM,RND,PMMCF 1 - 1 - 1 
Total 22 12 9 3 1 
 
 
Procedure No Post RT Post CRT Recurrence Defaulter 
HM,SOHND,PMMCF 2 2 - - 1 
Total 2 2 - - 1 
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TABLE-17 
DISTRIBUTION OF PATIENTS ACCORDING TO ADJUVANT  
THERAPY 
 
Surgery Post surgery RT Post surgery CRT 
43 No % No % 
20 46.51 11 25.58 
 
Totally only 43 patients with SCC were operated as many opted for non 
invasive therapies for fear of disfigurement, prolonged hospitalization. Many 
patients also defaulted following CRT. On top of all, most presented late 
making surgery very difficult. 22 cases of tongue, 18 cases of buccal mucosa, a 
case of lip, and two cases of alveolus were operated. Totally six cases of 
recurrence were reported, three in the tongue and three in buccal mucosa. A 
postoperative death was also reported. Patients with recurrence were subjected 
to chemoradiotherapy (Table-16). Most of the patients received radiotherapy 
46.51% (20 cases) and chemoradiotherapy 25.58% (11 cases) following surgery 
for effective locoregional control (Table-17) (expect those who were operated 
for veruccous and ACC not). (Fig.11, 12, 13, 14, 15&16) 
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TABLE-18 
DISTRIBUTION OF PATIENTS ACCORDING TO RESPONSE TO 
CHEMORADIOTHERAPYT              
 
Site 
ChemoRT Response No response Defaulter % 
failure No No % No % No % 
Alveolus 14 3 4.41 3 4.41 8 11.76 16.17 
BM 27 6 8.82 4 5.88 17 25 42.64 
FOM 2 2 2.94 - - - - - 
HP 11 7 10.29 - - 4 5.88 5.88 
Lip 5 3 4.41 2 2.94 - - 2.94 
RMT 1 1 1.47 - - - - - 
Tongue 8 4 5.88 3 4.41 1 1.47 5.88 
Total 68 26 38.23 12 17.64 30 44.11 61.75 
Chemoradiotherapy was given as the definitive treatment for advanced stages                          
(stage 3 and 4) at a dose of 66 Gy (2.0 Gy/day for 5 days/week for a total of 6 
weeks in 28-35 sittings) for primary and 50 Gy (2.0 Gy/day for 5 days/ week for 
a total of 6 weeks) for neck combined with cisplatin at a dose of 100 mg/ m2, 5-
FU at 1000 mg/m2as infusion on 1,22nd and 43rd days. Of the 41.97% (68 cases) 
persons who were treated with chemoradiation 38.23% (26 cases) showed a 
response whereas17.64 %( 12cases)   had residual disease and underwent 
salvage surgery. 44.11% (30 cases) defaulted. 
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                                                      TABLE-19 
DISTRIBUTION OF PATIENTS ACCORDING TO SALVAGE 
SURGERY 
Surgery Site No Recurrence Defaulter Death 
CRT,CR,PMMCF, RND BM 3 - 1 - 
CRT,WLE,FHF, SOHND BM 1 - - - 
CRT,CR,PMMCF, RND Tongue 2 - 1 - 
CRT,HG,SOHND 
 
Tongue 1 - - 
- 
CRT,WLE,ERF, SOHND Lip 2 - - - 
CRT,CR,PMMCF, RND Alveolus 3 - - - 
Total 12 - 2 - 
 
Of the 17.64% (12 cases) who underwent salvage surgery there was no 
recurrences whereas two patients defaulted.      
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TABLE-20 
DISTRIBUTION OF PATIENTS ACCORDING TO RESPONSE TO 
RADIOTHERAPY 
 
Site 
 
No 
Response No response Defaulter % 
failure No % No % no % 
Alveolus - - - - - - - - 
BM 10 - - 8 19.51 2 4.88 4.88 
FOM 2 - - - - 2 4.88 4.88 
Lip 2 - - - - 2 4.88 4.88 
HP 1 - - 1 2.43 - - - 
Tongue 26 - - 6 16.63 19 46.34 46.34 
Total 41 - - 15 36.59 25 60.98 97.56 
 
1 death occurred during treatment 
Overall 25.30% (41 cases) with advanced inoperable disease received palliative 
RT. 36.59% (15 cases) did not show any response. Most of the patients 60.98% 
(25cases) defaulted and one death was documented. On account of this attrition 
no meaningful outcome could be deduced. 
A patient with malignant melanoma was treated with chemotherapy. Follow up 
could not be done as the patient defaulted. 
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TABLE-21 
DISTRIBUTION OF PATIENTS ACCORDING TO RESPONSE TO                   
VARIOUS MODALITIES OF TREATMENT 
Regimen No 
Complete 
response 
Failure 
Death 
Defaulter 
No % No % No % 
Surgery+CT+RT 23 18 78.26 2 8.70 1 2 8.70 
Surgery+RT 20 16 80.00 2 10 - 2 10 
Surgery 21 18 85.71 2 9.52 - 1 4.76 
Chemo RT 68 26 38.23 12 17.64 - 30 44.11 
PalliativeRT 41 - - 15 36.58 1 25 60.98 
Chemotherapy 1 - - - - - 1 100 
 
The study revealed the fact that multimodal therapy had a very good outcome. 
78.26% (18 cases) of patients who received surgery with chemoradiotherapy 
showed a favourable outcome. Comparatively, patients who received surgery 
only showed a positive response of 85.71% (18 cases). Surgery combined with 
RT had a response of 80 %( 16 cases). Chemoradiotherapy had a poor outcome 
with 38.23% (26 cases) showing a positive response. Many of the patients who 
received palliative RT defaulted 60.98 %( 25 cases). Overall many patients 
defaulted 36.41% (59 cases) on account of lengthy treatment schedules, a slow 
response, numerous adverse effects and surgery associated morbidity.(Dia.17) 
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DISCUSSION 
 
 
Carcinoma of the Oral cavity is one of the most common carcinomas in India. 
(Elango et al.; Mehrotra et al.; Yeole et al., 2006). In Southeast Asia squamous 
cell carcinoma is the most commonly encountered oral cavity malignancy and is 
the sixth most common cancer worldwide (Al-Swiahb et al., 2010).Indian are at 
a high-risk for oral cancers due to a high prevalence of predisposing habits like 
tobacco chewing (in both sexes), smoking and alcohol consumption (in males) 
(Yeole et al., 2003). India accounts for around 25% of oral cavity cancers 
(Parkin etal., 1999). Apart from these risk factors, poor oral hygiene, dietary 
risk factors, low literacy levels, gender etc are associated with a high risk of oral 
cancer (Güneri et al., 2005).Despite improvements in diagnosis and loco-
regional treatment, there has not been any major increase in the long-term 
survival of oral cancer patients and it’s still low when compared with other 
major cancers worldwide (Swango, 1996; Shiboski et al., 2000). In a recent 
study, the observed 5-year survival rate in an Indian population was reported to 
be as low as 30.5% (Yeole et al., 2003). Such low survival rates can be 
attributed to advanced age and advanced clinical stage at time of presentation. 
Lots of factors influence the outcome of oral cavity cancers; tumour-related 
factors like the degree of differentiation, site of tumour, size of tumour, etc to 
name a few. The present study is aims to analyze the incidence of oral cancers, 
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discuss various risk factors, determine the median stage of presentation, and 
assess the various modalities of treatment strategies 
 
Our study comprised 162 patients, 100 of which were male and 62, female. The 
gender distribution we got in our study correlated with a few of the studies in 
the recent past (Mehrotra et al.). Some studies have reported a higher incidence 
of oral cavity cancers in females (Kumar et al., 2001; Güneri et al.). Few other 
studies have reported an increasing trend of oral cavity cancers in females 
(Gaitán-Cepeda et al., 2010; Girod et al., 2009). 
 
Our study showed a ratio of 1.61:1 favoring males. This was consistent with 
certain European studies88, the Alberta study (ratio of 2:1), in United States 
(ratio of 3:1) and studies from Pakistan & India all of which showed a male 
predominance. In high risk countries like India, Pakistan and Bangladesh, and 
Srilanka, oral cavity cancers are the most common cancer in men and account 
for up to 30% of all new cases of cancer compared to just 3% in the UK and 6% 
in France.90 This trend is due to the greater use of tobacco, betel nut and alcohol 
by men than women in these countries. Greece reported a higher number of 
female cases. (Zavras A.I., et al).another study from Lahore89 also showed 
female predominance with the ratio of 1.5:1. 
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 The risk of developing oral cancer increases as one ages91. In our study 70.98% 
cases were over 50 years of age with the majority of patients presenting in the 
sixth and seventh decade. In the Alberta cancer registry, the maximum 
incidence was noted in the fifth and sixth decades. The average age of onset in 
the United States was in the fifth decade and the mean age of diagnosis is 65 
years (national cancer institute SEER programme) and more than 50% of cases 
occurred above the age of 60 years. In the UK most of the cases (86%) were 
above 50 years.92 
 
In our study majority of patients (99.38%) with oral cancers were from a low 
socio-economic status. 
 
The most common site involved in our study was the buccal mucosa (36.42%), 
followed by the tongue (35.18%), though the difference was only 1.24%. 
According to western literature (Watkinson et al., 2000; Rivera et al.) oral 
tongue is considered to be the most commonly involved sub site in the oral 
cavity. Two cancer centers in the United States reported an increase in the 
proportion of oral tongue cancers diagnosed in men younger 40 years.93-94 It was 
later confirmed after analyzing Scottish data that this increase was not restricted 
to the under 40 population but could be detected in all age groups till 65 years. 
 
The most common risk factors identified in our study were betel nut, tobacco 
chewing (47.53%), smoking and alcohol intake. This was consistent with other 
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studies (Güneri et al.). Other risk factors included a low socio-economic status, 
gender, dietary habits and poor oral dental hygiene. The relatively higher 
incidence of buccal mucosa carcinoma in India can be attributed to our practice 
of chewing tobacco (Mehrotra et al.; Kumar et al.). 
 
Majority of the patients reported an ulcer 151 cases in the mouth. Tumors of the 
oral cavity often ulcerate due to friction of the mucous membrane during eating 
and also due to infection. Though the lesions are initially painless, advanced 
lesions are often associated with pain. Other symptoms reported were excessive 
salivation, difficulty in chewing, dysphonia, dysphagia and ankyloglossia and 
trismus. 
 
 Squamous cell (93.83%) carcinoma was the most commonly encountered 
histological variety followed by Adenoid cystic carcinoma (1.85%), verrucous 
carcinoma (3.70%) and melanoma (0.62%). The National Cancer Data Base of 
USA shows the following data SCC - 86.3%, Verrucous - 2.0%. Further, 44.4% 
cases were well differentiated, 34.57% of cases were moderately differentiated 
and 14.81%% were poorly differentiated. This correlates with studies by 
Khanna et al. We did not encounter any case of multicentric origin of SCC as 
described by Slaughter DP et al. The degree of differentiation is an important 
prognostic factor in oral cavity cancers. Poorly differentiated cancers have a 
worse prognosis compared with well differentiated ones (Weijers et al.; Al-
Swiahb et al., 2010). There can also be an association between the degree of 
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differentiation of the cancer and metastasis to regional lymph nodes, with less 
differentiated cancers more likely to metastasize (Rivera et al.). 
 
Most of the patients presented with an ulcerative growth (58.03%). 
Ulceroproliferative growth was the second most common (36.42%) 
Proliferative pattern of growth was the least common (5.55%). These results 
were consistent with (Wahi et al1965, Khanna et al1985, Mehta 1990). 
 
Most of the tumours we encountered were advanced. 48.76% of patients 
presented in stage IV and 32.10% of patients presented in stage III. In our study 
50% of patients had T4 lesion and 26.54% had T3 lesion.29.63% of patients 
presented with N1, 53.69% of patients had N2 disease and 2.47% of patients 
presented with N3. This was in concordance with S Manuel et al and Y Okada 
et al96-97 where cases presented early T3- 33.9% and T4- 43.2% and N1 19.5%, 
N2 43.2% and N3 28%. Compared to MD Anderson cancer center study and 
National Cancer Database Study the proportion of N0 neck was very low in our 
study 14.20%. This pattern of late stage of presentation could be due to low 
literacy rate, ignorance regarding the disease and poor referral system in our 
country.  
 
 
Out of 162 patients in the study, 39.51% (64 cases) of patients underwent 
surgery for SCC, ACC and verrucous carcinoma, and salvage procedure after 
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chemoradiotherapy for residual lesion. Of these 32.81% (21 cases) patients 
managed with surgery alone showed good response 85.71%.this studies 
compared with Rodgers et al. 31.25% (20 cases) patients treated with surgery 
and postoperative radiotherapy showed response 80%.This was consistent with 
other studies Rodgers et al, Pernot et al98 Lundahl et al Medical College of 
Virginia. 35.94% (23 cases) managed with multimodal treatment showed 
response rate 78.26%.These results were consistent with EORTC and RTOG 
studies99-102 Janot et al. Surgery could not be performed on all patients because 
many of the patients presented late thus ruling out surgery, general condition of 
many patients was poor and presence of other co-morbid conditions 
contraindicated surgery, fear of surgery and failure to accept the limitations of 
surgery excluded many patients and the limited usefulness of surgery in 
advanced lesions further reduced the number of patients. Both radiotherapy and 
surgery are equally effective for early lesions. (Fein et al 2002,104 M Krishnan 
Nair, R Sankaranarayanan). None of our patients received primary radiotherapy. 
One patient was treated with chemotherapy. 41.98%(68 cases) patients were 
treated with chemoradiotherapy, 38.23% (26 cases) of these patients responded 
well while 17.64%(12 cases) had a poor response and underwent salvage 
surgery, and failure rate of 61.75%.This was consistent with other studies 
Adelstein et al.102 Palliative RT was given to a total of 25.31%(41 cases), 
36.59% (15 cases) did not respond well and 60.98%(25 cases) defaulted. 
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 For patients with early disease Stage I and II, a single modality treatment with 
either surgery or radiotherapy is recommended as survival benefit is similar in 
both these modalities.  In contrast, in patients with locally advanced disease and 
advanced disease require a combined modality approach. Since the majority of 
oral cancers present at an advanced Stage III and IV, the therapy is more 
complex the prognosis guarded.105 Surgery and radiation used together gives the 
maximum survival benefit at the cost of increased morbidity and complication. 
Role of chemotherapy is still unclear in oral squamous cell carcinoma. 
 
Follow up was done monthly for the 1st year and once in 3months for the 2nd 
year during which six recurrences were reported in patients who were operated. 
Recurrences were managed with chemoradiotherapy. Out of 68 patients 
subjected to chemoradiotherapy, no recurrences were reported. 
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CONCLUSIONS 
 
• The most common cancer of the oral cavity that we encountered was 
squamous cell carcinoma which accounted for 93.83% of the cases.  
• In our study the buccal mucosa was most commonly involved (36.42%) 
followed    by   the tongue (35.18%) though the difference was negligible. 
• Incidence of oral cancer was found to be highest in the 6th & 7th decades 
31.48% & 30.25% respectively. 
• There was a definite   male   preponderance with a male to female sex 
ratio of1.61:1. 
• The most common etiological factor (in 47.53% of cases) was the habit of 
chewing betel leaf and tobacco with slaked lime (quid).It was also 
apparent that this habit was much more common in females 32.10% 
against 15.43% for males. 
• The commonest mode of presentation in our study was an ulcer 93.0%. 
• Majority of patients had an ulcerative type of growth 58.03% against 
5.55% with a proliferative growth and 36.42% with an ulceroproliferative 
pattern of growth. 
• Almost all of the cases were from a low socioeconomic stratum 99.38%. 
• Lack of awareness among the general public about oral cancers and non 
availability of mechanisms for early diagnosis and referral are probably 
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the reasons for majority of patients presenting in Stage III 32.10% and IV 
48.76% in our study. 
• There were no cases of distant metastasis Stage IVC 
• Management of early oral cancers (Stage I & Stage II) with surgery 
yielded a good result; complete response was seen in 85.71% of cases. 
Likewise advanced stages were managed with a multimodal approach- 
either surgery with chemoradiotherapy in which 78.26% cure rate was 
achieved or surgery with radiotherapy alone in which 80.0% cure rate 
was seen. 
•  A post operative mortality was encountered. 
• 41.97% of patients were given primary chemoradiotherapy and 38.23% 
responded completely while 17.64% of patients had residual disease and 
underwent salvage surgery. 
• Around 25.30% of patients who presented late and who had inoperable 
tumours were managed with palliative radiotherapy.  
• Our study was confounded by 36.41% defaulters. The recurrence rate was 
9.38% following surgery. 
• So we conclude that early lesions can be successfully managed with 
single modality treatment, either surgery or radiotherapy while advanced 
cases definitely requires a multimodal approach.  
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FIG.3. ORAL SUBMUCOUS FIBROSIS 
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FIG.4. LEUKOPLAKIA IN TONGUE 
 
 
 
FIG.5. ADENOID CYSTIC CARCINOMA IN HARD PALATE 
 
 
 
 
 
FIG.6. CARCINOMA BUCCAL MUCOSA PREOPERATIVE VIEW 
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FIG.7. CARCINOMA BUCCAL MUCOSA POSTOPERATIVE VIEW 
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FIG.11&12. CARCINOMA BUCCAL MUCOSA WITH 
OROCUTANEOUS FISTULA AND COMPOSITE RESECTION WITH 
RND 
 
 
FIG.13. RECONSTRUCTION WITH PMMCF 
 
 
FIG.14 &15. CARCINOMA TONGUE AND EXTENDED 
SUPRAOMOHYOID NECK DISSECTION 
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FIG.16. DURING HEMIGLASSECTOMY 
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WIDE LOCAL EXCISION 
119 
 
 
 
FIG.10. CARCINOMA LIP AFTER RECONTRUTION WITH ERF 
 
 
            
 
 
 
 
 
120 
 
BIBLIOGRAPHY  
1. Cawson RA, Langdon JD, Eveson JW. Surgical pathology of the mouth 
andjaws, 3rd ed.1996. 
2.Regezi JA, Sciubba JJ, Jordan RCK. Oral pathology; clinical pathologic    
considerations. 4thed. 2003.WB. Saqunders, Philadelphia. 
3. Ahmed HG, Ebnoof SO, Hussein MO, Gbreel AY. Oral epithelial 
atypicalchanges in apparently healthy oral mucosa exposed to smoking, 
alcohol,peppers and hot meals, using the AgNOR and Papanicolaou 
stainingtechniques. Diagn Cytopathol. 2009; 15(5):973-978. 
4. Mehta FS, Aghi MB, Gupta PC, Pindborg JJ. An intervention study of 
oralcancer and pre-cancer in rural Indian population. Bull. WHO 1982; 60: 441-
6 
5.American cancer society:cancer facts and figures. Atlanta, American 
cancersociety,1996.  
6. Constatntinides MS, Rothstein SG, Persky MS: Squamous cell carcinomas in 
Older patients without risk factors Otolaryngol head neck surg 106:275-277, 
1992. 
7. Mallowala AM, Silverman S, Mani NJ, et al:oral cancer in 57518 industrial 
workers in Gujarat, India .cancer 37:1882-1886.1976. 
121 
 
 
8.Bailey and Love’s short practice of surgery, 25th edition, Chapter 46, page734. 
9. Schwartz’s principles of surgery ninth edition Chapter 18. Page 503. 
10.International agency for research on cancer: Tobacco smoking. 
IARCMonogr Eval Carcinog Risk      Chem Hum 38.yon, 1986. 
11. Macfarlene GJ, Zheng T, Marshall JR, et al: alcohol, tobacco, diet and 
therisk of oral cancer: A pooled analysis of three case control studies. Eur 
JCancer B Oral Oncol 31B:181-187,995.  
12. EU Working group on tobacco and oral health: Tobacco an oral diseases-
report of EU Working group, 1999 J Ir Dent Assoc 46:12-19, 22, 2000. 
13. ShapiroJA, Jacobs EJ, Thun MJ: Cigar smoking in men and risk of 
deathfrom tobacco related cancers.J Natl cancer Inst92:333-33,2000. 
14. Winn DM, Blot WJ, Shy CM,et al: snuff dipping and oral cancer 
amongwomen in southern United States. N Engl J Med05:745-749,1986. 
15.Franceschi S, Talamani R, Barra, et al: Smoking and drinking in relation to 
Cancers of the oral cavity, pharynx, larynx and esophagus in 
NorthernItaly,Cancer Res 50:6502-6507.1980. 
122 
 
16.Schlecht, Frnaco,Pintos et al:effect of smoking cessation and tobacco type 
onrisk of cancers of upper aerodigestive track in Brazil. Epidemiology 10:412-
418, 1999. 
17. Ko YC, Huang YL, Lee CH, et al Betel quid chewing, cigarette smoking 
And alcohol consumption related to oral cancer in Taiwan J Oral Pathol Med 
24:450-453, 1995. 
18.Muscat JE, Richie JP, Thompson S, et al Gender differences in smoking and 
Risk for oral cancer.Cancer Res 56:5192-5297, 1996. 
19.Rothman KJ, Keller AZ: The effect of joint exposure to alcohol and tobacco 
On the risk of cancer of the mouth and pharynx J Chron Dis 25:711-7161972. 
20.Brugere J, Guene LP, Leclerc A, et al:Differential effects of alcohol and 
Tobacco in cancer of the larynx, pharynx and mouth.Cancer 57:391-395, 1986. 
21. Cancer statistics .CA Cancer J Clin 35:19, 1985. 
22. Llewelyn J Mitchell R: Smoking,alcohol and oral cancer in south east 
Scotland: A 10 year experience. Br J Oral Maxillofacial Surg 32:146-152, 1994. 
23. Larsson PA, Johannson SL, Vahlne et al:Snuff tumourigenesis:Effects 
oflong term snuff administration after initiation with 4-nitroquinolone N-oxide 
and herpes simplex virus type-1 J Oral Pathol Med 18:187-192, 1989. 
123 
 
24. Miller CS, Johnstone BM, Human papilloma virus as a risk factor for 
oralsquamous cell carcinoma:A meta analysis, 1982-1997 Oral Surg Oral 
MedOral Pathol Oral Radiol 91:622-635,2001. 
25. Shin KH Tannyhill RJ, Liu X et al: Oncogenic transformation of HPV –
immortalized human oral keratinocytes is associated with genetic instabilityof 
cells Oncogene12:1089-1096, 1996. 
26.Firth NA: Marijuana use and oral cancer: A review Oral Oncol6:398-
401,1997. 
27. Largon LG Sandstorm A, Westling P: Relationship of Plummer-Vinson 
disease to cancer of upper alimentary tract in Sweden Cancer Res 35:3308-
3316, 1975. 
28. Day GL, Shore RE, Blot WJ, et al Dietary factors and second primary 
cancers: A follow up of oral and pharyngeal cancer patients. Nutr Cancer 
21:223-232, 1994. 
29.  Maier H, Zoller J, Herrmann A et al, Dental status and oral hygiene in 
patients with head and neck cancer. Otolaryngol Head and Neck Surg 108:665-
661, 1993. 
30.Velly AM, Franco EL, Schlecht N,et al: Relationship between dental factors 
and risk of upper aerodigestive cancer. Oral Oncol 34:284-291, 1998. 
124 
 
31.Homann N, Tillonen J, Rintamaki H, et al:Poor dental status increases 
acetaldehyde production from ethanol in saliva: A possible link to increased 
oral cavity cancer risk among heavy drinkers OO37:153-158, 2001. 
32.Faron ER, Vogelstein B; A genetic model for colorectal tumor genesis. Cell 
6; 2488-1996. 
33.Grandis JR Tweardy DJ; Elevated levels of transforming growth factor alpha 
and epidermal growth factor receptor messenger RNA are early markers of 
carcinogenesis in head and neck cancer. Cancer Res 53; 3579-3584, 1993 
34.Ford AC, Grandis JR: Targeting epidermal growth factor receptor in head 
and neck cancer 25:67-73, 2003 
35.Forastiere A, Koch W, Trotti Aet al: head and neck cancer.  New Engl J Med 
345:1890-1900, 2000 
36.Van der Riet P, Nawroz H, Hruban RH, et al: Frequent loss chromosome 
9p21-22 early in head and neck cancer progression. Cancer res 54:1156-1158, 
1994. 
37.El-Naggar AK, Lai S, clayman GL, et al: expression of p16, Rb, an cyclin 
D1 gene products in oral and laryngeal SCC. Biological and clinical 
implication. Hum Pathol 30:1013-1018, 1999. 
125 
 
38.Bova RJ, Quinn DI, Nankervis JS, et al: Cyclin D1 a p16INK4A expression 
predict survival in carcinoma of the anterior tongue. Clin cancer Res 5:2810-
2819, 1999. 
39.World Health Organization Collaborating Center for Oral Precancerous 
Lesions: Definition of leukoplakia and related lesions.An aid to studies on 
precancer. Oral Surg 46:518-539, 1978 
40.Kannan S, Balram P, Pillai MR, et al: Ultrastructural variations and 
assessment of malignant transformation risk in oral leukoplakia.  Pathol Res 
Pract 189:1169-1180, 1993. 
41.Cawson RA, Odell EW: Essentials of Oral Pathology and Oral Medicine, 6th 
Ed. New York, Churchill Livingstone, 1998. 
42.Silverman S, Gorsky M, Lazoda F: Oral leukoplakia and malignant 
transformation- a follow up study of 257 patients.Cancer 53:563-568, 1984. 
43.Krammer IRH, El-Lablan D, Lee KW:The clinical features and risk of 
malignant transformation in sublingual keratosis. Br Dent J 144:171-180, 1978. 
44.Noisome T,Chiba H, Itch M,et al:Bal-x (L) confers multidrug resistance in 
several squamous cell carcinoma cell lines. Oral Oncol 38:41-48, 2002. 
45. Kokal WA, Gardine RL, Sheibani K: Tumour DNA content as a prognostic 
indicator in squamous cell carcinoma of head and neck region. Am J Surg 
156:276-280, 1988? 
126 
 
46.Broders AC:Squamous cell epithelioma of the lip. JAMA 74:656-664, 1920. 
47.Anneroth G,Batsakis J, and Luna M: Review of literature and a 
recommended system of malignancy grading in oral squamous cell carcinoma. 
Scant J Dent Res 95:229-249, 1987. 
48.Kraus FT, Perez-Mesa C: Verrucous carcinoma: Clinical and pathological 
study of 105 cases involving oral cavity, larynx and genitalia. Cancer 19:26-38, 
1966. 
49.Medina JE, Ditched W, and Luna MA:Veruccous squamous carcinomas of 
the oral cavity: a clinicopathological study of 104 cases. Arch Otolaryngol Head 
and Neck Surgery 110:437-444, 1984. 
50. Krupala JL, Gianoli R: Carcinoma of the oral tongue. J La State Med Soc 
145; 421-426, 1993. 
51.Coppola D, Catalano E, Tang C et al: Basaloid squamous cell carcinoma of 
floor of mouth. Cancer 72:2299-2305, 1993. 
52.Winzenburg SM, Neihans GA, George E, et al: Basaloid squamous cell 
carcinoma: A clinical comparison of two histologic types with poorly 
differentiated squamous cell carcinoma. Otolaryngol Head and Neck Surgery 
119:471-475, 1998. 
53.Weber RS, Palmer JM,El-Nagger A,et al:Minor salivary gland tumours of 
the Lip and buccal mucosa. Laryngoscope 99:6-9, 1989. 
127 
 
54. Van der Waal JE, Snow GB, Karim A et al: Intraoral adenoid cystic 
carcinoma: The role of post-operative radiotherapy in local control. Head neck 
11:497-499,1989. 
55. Van der Waal JE, Snow GB, Van der Waal I: Intraoral adenoid cystic 
carcinoma-the presence of perineural spread in relation to site, size, local 
extension, and metastatic spread in 22 cases. Cancer 66:2031-2033, 1990. 
56.Spiro RH, Koss LG, Hajdu SI et al: Tumours of the minor salivary gland 
origin: A clinicopathological study of 492 cases. Cancer 31:117-129, 1973. 
57.Khan AJ, Digiovanna GMP, Ross DA et al: Adenoid cystic carcinoma: A 
retrospective review. Int J Cancer 96:149-158, 2001. 
58.Smyth AG, Ward-Booth RP, Avery BS et al: Malignant melanoma of the 
oral cavity-an increasing diagnosis? Br J Oral Maxillofac Surg 31:230-235, 
1993. 
59.Rapini RP, Golitz LE, Greer RO et al: Primary, malignant tumour of the oral 
cavity: A review of 177 cases. Cancer 55:1543-1547, 1985. 
60.Taylor C, Lewis JS: Histologically documented transformation of benign 
oral melanosis into malignant melanoma. J Oral Maxillofac Surg 48:732-737, 
1990. 
61. Canto MT, Devessa SS: Oral cavity and pharynx cancer incidence rates in 
United states, 1975-1988. Oral Oncol 38:610-617, 2002. 
128 
 
62.Freeman C, Berg JW, and Cutler SJ: Occurrence and prognosis of extra 
nodal lymphomas: Cancer 29:252-260, 1984. 
63.Takahashi N, Tsuda N, Tezuka F et al:Primary extra nodal Hodgkin’s 
lymphoma of the oral region. J Oral Pathol Me 18:84-91, 1993. 
64. Zitsch RP: Carcinoma of the lip. Otolaryngol Clin North Am 26;265-277, 
1993. 
65. AJCC: American Joint Committee for Cancer Staging and End Results 
Reporting. Chicago, American Joint Committee on Cancer, 1998. 
66. Lindberg RD. Distribution of Cervical lymph node metastases from 
squamous cell carcinoma of the upper respiratory and digestive tracts. Cancer 
1972; 29; 1446. 
67. Piccirillo JF: Purposes problems and proposals for progress in cancer 
staging. Arch Otolaryngol Head and Neck Surg 121:145-149, 1995. 
68. Byer RM, Weber RS, Andrew T, et al: Frequency and therapeutic 
implications of skip metastases in the neck from squamous cell carcinoma of the 
oral tongue. Head Neck 19:445-446, 1997. 
69.Shah JP, Medina JE, Shaha AR, et al: Cervical lymph node metastases Curr 
Prob Surg 30:273-344, 1993. 
129 
 
70. Ferlito A, Shaha AR, Silver C, et al: Incidence and sites of distant 
metastases in head and neck cancers. ORL J Otolaryngol Relat Spec 63:202-
207, 2001. 
71. Friedman M, Mafee MF, Pacella BL, et al: Rationale for elective neck 
dissection in 1990. Laryngoscope 100:54-59, 1990. 
72. Calemeyer KS, Matthews VP, Righi PD, et al: Imaging features and clinical 
significance of perineural spread or extension of head and neck tumours.Radio 
graphics 18:97-110, 1998. 
73. Van den Brekel MW, Castelijns JA, Stel HV, et al: Modern imaging 
techniques and ultrasound guided aspiration cytology for the assessment of neck 
node metastases. A prospective comparative study. Eur Arch Otolaryngol 
259:11-17, 1993. 
74. Farber LA, Benard F, Machtay M et al: Detection of recurrent head and 
neck squamous cell carcinoma after radiation therapy with 2-18F-fluoro-2-
deoxy-D-glucose positron emission tomography: Laryngoscope 109:970-975, 
1999. 
75.Barry W. Feig, MD, C. Denise Ching, MD, The MD Anderson surgical 
oncology Handbook, Fith edition chapter 6 cancer of head and neck page no 
196-207. 
130 
 
76. Devita, Hellman& Rosen bergs, Principle & Practice of oncology, Chapter 
36 head & carcinoma page no 809-876.  
77.Eugene.N.myers, James Y.suen Jeffrey N.myers, Ehab Y.N, Text book of 
head & neck, chapter 13, page no 279-319. 
78. King JM, Caldarelli DD, Petasnick JP, Dentascan(TM): A new diagnostic 
method for evaluating maxillary and mandibular pathology. Laryngoscope 
102:379-387, 1992. 
79. Crile G: Extension of cancer of the head and neck: With special reference to 
the plan of dissection based on 132 operations. JAMA 47:1780-1785, 1906. 
80. Department of Veteran Affairs Laryngeal Study Group. Induction 
chemotherapy plus radiation compared with surgery with radiation in patients 
with advanced laryngeal cancer. N Engl J Med 324:1685-1690, 1991. 
81.Tishler RB, Norris CM, Colevas AD, et al: A phase I/II trial of concurrent 
docetaxel and radiation after induction chemotherapy in patients with poor 
prognosis squamous cell carcinoma of the head and neck. Cancer 95:1472-1481, 
2002. 
82. Jacobs C, Makuch R: Efficacy of adjuvant chemotherapy for patients with 
resectable head and neck cancer. A subset analysis of the Head and Neck 
Contacts Program. J Clin Oncol 8:838-847, 1990. 
131 
 
83.Vokes EE, Kies MS, Haraf DJ, et al: Concomitant chemotherapy as primary 
therapy for locoregionally advanced head and neck cancer. J Clin Oncol 
18:1652-1661, 2000. 
84.Schuller DE, Metch B, Stein DW, et al: Preoperative chemotherapy in 
advanced resects able head and neck cancer. Final report of the southwest 
oncology group. Laryngoscope 98:1205-1211, 1988. 
85.Forasteire AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and 
radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 
2003:349:2091-2098. 
86.JatinShaw, text book of head & neck surgery & oncology, chapter-6, pages 
no 173-232. 
87.Bonner JA, Harari PM, Giralt J,et al. Radiotherapy plus cetuximab for 
squamous cell carcinoma of the head and neck. N Engl J Med 2006:354:567-
578. 
88. Christopher L.B. Lavellea, Crispian Scullyb. Criteriato rationalize 
population screening to control oralcancer. January, 2005; Volume 41, Issue 1: 
Pages 11 –16. 
89. Mubashir Ali, Aftab H Bhatti, M Tariq, Shamim A Khan, Ghulam Sarwar, 
Khalid Waheed, Nadeem Anwar, A Majeed Akhtar. An Epidemiological Study 
132 
 
of 202 Cases of Oral Cavity Cancer (OCC) in Pakistani Subjects Biomedical 
Jan - Jun 1998; 14: 27-31. 
90. Scully C, Bedi R. Ethnicity and oral cancer. Lancet Oncol. 2000 Sep; 1 (1): 
37-42. 
91. Office for national statistics. Cancer statistics registrations: registrations for 
cancer diagnosed in 2004, England. Series MBI no. 35. 2007. 
92. Scully C, Sudbø J, Speight PM. Progress in determiningthe malignant 
potential of oral lesions. J Oral PatholMed. 2003 May; 32 (5): 251-6. 
93. Shemen LJ, Klotz J, Schottenfeld D, Strong EW. Increase of tongue cancer 
in young men. JAMA 1984; 252: 
1857. 
94. Schantz SP, Byers RM, Goepfert H. Tobacco and cancer of the tongue in 
young adults. JAMA 1988; 259:1943–1944. 
95. Manuel S, Raghavan SKN, Pandey M, Sebastian P. Survival in patients 
under 45 years with squamous cell carcinoma of the oral tongue. Int J Oral 
Maxillofac Surg 2003; 32: 167-73.  
96. Torossian JM, Baziat JL, Philip T, Bejui FT. Squamous cell carcinoma of 
the tongue in a 13-years-old boy. J Oral Maxillofac Surg. 2000; 58: 1407-10.  
97. Okada Y, Mataga I, Katagiri M, Ishii K. An analysis of cervical lymph 
nodes metastasis in oral squamous cell carcinoma. Relationship between grade 
of histopatho-logy malignancy and lymph nodes metastasis. Int J Oral 
Maxillofac Surg 2003; 32: 284 
133 
 
98.Pernot M, Hoffstetter S,Peiffert D, et al, Epidermoid carcinomas of the floor 
of mouth treated by exclusive irradiation: statistical study of a series of 207 
cases, Radiother Oncol 1992;2;171. 
99.Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent 
radiotherapy and chemotherapy for high- risk SCC of the head and neck. N Engl 
J Med 2004;350:1937-1944. 
100. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or 
without concomitant chemotherapy for locally advanced head and neck cancerN 
Engl J Med 2004;350:1945-1952. 
101. Cooper JS, Pajak TF, Forastiere AA, et al. Long-term survival results of a 
phase III intergroup trial (RTOG 95-01) of surgery followed by radiotherapy vs. 
radio chemotherapy for resect able high risk HNSCC. (Abstr) Int J Radiat Oncol 
Bio Phy 2006;66:S14-S15 
102. Adelstein DJ, Lavertu P, Saxton JP, et al. Mature of a phase III randomized 
trial comparing concurrent chemoradiotherapy with radiation therapy alone in 
patients with stage III and IV HNSCC. Cancer 2000;88:876-883. 
103.Brizel DM, Wasserman TH, Henke M, et al. Phase III trial of amifostine as 
a radio protector in HNSCC. J Clin Oncol 2000; 18: 3339-3345. 
104. Fein, D.A., Mendenhall, W.M. and Parsons, J.T. 2002. Carcinoma of the 
oral cavity: A comparison of results and complication of treatment with 
radiotherapy and or surgery 
134 
 
105. Bernier, J. et al (2004), Post operative irradiation with or without 
concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. 
J. Med. 350:1945. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
135 
 
PROFORMA 
Name 
 
Age 
 
Sex 
 
Occupation 
 
Income 
 
Address 
 
Contact no 
 
Socio economic status 
 
IP no 
 
Date of admission 
 
Date of surgery 
 
Date of discharge 
 
TNM stage  
 
Diagnosis 
 
Symptoms: 
 
1. Ulcer / Swelling / Growth 
2. Pain / radiating pain 
3. Bleeding 
4. Excessive salivation 
5. Change in voice 
6. Alteration in taste 
7. Loss of weight / appetite 
8. Difficulty in mouth opening 
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9. Recent dental extraction 
10. Any other complaints 
Other co morbidities 
   DM / HT / TB / COPD 
Risk factors 
1. Chronic smoking 
2. Alcohol abuse 
3. Chronic betel nut & tobacco chewing 
4. Sharp teeth & dentures 
5. Chronic oral sepsis 
6. Spicy food intake  
7. Radiation exposure 
Examination of oral cavity 
Premalignant lesions: 
   1. Leukoplakia 
   2. Erythroplakia 
   3. Submucous fibrosis 
   4. Canidiasis 
Site: 
        Lips – upper / lower / angle of mouth 
        Buccoalveolar sulci 
        Retromolar 
        Cheek 
        Alveolus – upper / lower 
        Tongue – anterior 2/3 
        Floor of mouth 
        Hard palate          
Size 
Extent  
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Type 
Tenderness 
Floor & base 
Bleeds on touch 
Mouth opening 
Oral hygiene 
Dental formula 
Orocutaneous fistula 
Nodal status 
Investigation: 
1. X-ray mandible 
2. X-ray chest 
3. CT – scan 
4. Biopsy5. Fnac of node 
Treatment: 
 
Curative / Palliative 
 
Neoadjuvant therapy 
 
Surgery done: 
 
RT – curative / palliative 
 
Chemo – drugs, cycles, response 
 
Outcome: 
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ABBREVATION  
• FOM    : Floor of mouth 
• RMT  : Retro molar trigone 
• HP       : Hard palate 
• BM       : Buccal mucosa 
• U              : Ulcer 
• P          : Pain 
• S           : Swelling 
• ES         : Excessive salivation 
• D                  : Dysphagia 
• T            : Trismus 
• RE          : Retro molar extension 
• OCF           : Orocutaneous fistula 
• DC                 : Difficulty in chewing 
• LN             : Lump neck 
• AG               : Ankyloglossia 
• T                   : Tobacco 
• S               : Smoking 
• A                   : Alcohol 
• B    : Betel nut 
• PM LESIONS   : Pre malignant lesions 
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• L                   : Leukoplakia 
• E              : Erythroplakia 
• SMF       : Sub mucosal fibrosis 
• C                    : Candidiasis 
• ND                    : Nutritional deficiency 
• DF                : Dental factors 
• U                    : Ulcerative 
• UP             : Ulceroproliferative 
• P                   : Proliferative 
• SCC                   : Squamous cell carcinoma 
• MM                : Malignant melanoma 
• VC                 : Verrucous carcinoma 
• SE status       : Socioeconomic status 
• L                    : Low 
• M                      : Middle 
• WLE                  : Wide local excision 
• HM                  : Hemimandibulectomy 
• HG                  : Hemiglossectomy 
• CR                      :   Composite resection 
• SOHND             :    Supraomohyoid neck dissection 
• ESOHND    : Extended supraomohyoid neck dissection 
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• RND               : Radical neck dissection 
• PMMCF        : Pectoralis major myocutaneous flap 
• ERF               : Estlander rotating flap 
• FHF              : Forehead flap 
• DPF               : Deltopectoral flap 
• NLF                : Nasolabial flap 
• CRT                : Chemoradiotherapy 
• POST CRT      : Postoperative chemoradiotherapy 
• PALRT           : Palliative Radiotherapy 
• CHEMORT    : Chemoradiotherapy 
• POSTRT        : Postoperative Radiotherapy 
• REC                : Recurrence 
 
 
 
MASTER CHART
S.NO          NAME AGE SEX REG NO        SITE TNM SYMPTOMS RISK FACTORS PM LESIONS SE STATUS TYPE GRADE CLINICAL PATTERNS TREATMENT FOLLOW-UP
1 Ramaswamy 68 M 10759/11 Tongue-R T2N2bM0 U,S B,T SMF L SCC I UP HG,RND,POSTCRT ASYMPTAM
2 Ganasekaran 53 M 10856/11 Buccal mucosa-L T1N0M0 U,P,ES,DC S,A E L SCC II U WLE,FHF ASYMPTAM
3 Ibrahim ammal 68 F 21215/11 Tongue-L T1N0M0 P,A,ES,U B,T SMF L SCC II U WLE,SOHND PROGR
4 Avadaichi 63 F 24078/11 Lip-Comm T2N0M0 S B,T E L VC P WLE,FHF ASYMPTAM
5 Ayyammal 60 F 25932/11 Lip-Lower T4N2cM0 U,S B,T SMF L SCC III UP PAL-RT DEFAULT
6 Kamatchi 49 M 25994/11 Buccal mucosa-L T4N2bM0 U B,S L SCC II U CHEMORT DEFAULT
7 Ayyakal 53 M 27332/11 Tongue-L T2N2bM0 U B,S,A L,E L SCC I U HG,RND,POSTCRT ASYMPTAM
8 Vellapillai 60 M 28340/11 Buccal mucosa-L T3N1M0 U,S B,T,S L L SCC I UP CHEMORT ASYMPTAM
9 Chinnakannu 57 M 28418/11 Lip-Lower T3N1M0 S,P,U B,T,A L L SCC I UP CHEMORT ASYMPTAM
10 Vellaiswamy 70 M 28529/11 Buccal mucosa-L T1N1M0 U,S B,T L L SCC I UP WLE,FHF,SOHND,POSTRT DEFAULT
11 Ramalakshmi 40 F 32675/11 Tongue-L T1N0M0 P,A,ES,U,S L SCC II UP WLE,SOHND DEFAULT
12 Jeyaram 58 M 33149/11 Buccal mucosa-R T4N2bM0 U B,T,A L,E L SCC II U CHEMORT DEFAULT
13 Ganasekar 99 M 35186/11 Tongue-L T2N2bM0 U,S L SCC I UP HG,RND,POSTCRT ASYMPTAM
14 Chandran 59 M 72032/12 Alveolus T2N0M0 U,S B,T,S L L SCC II UP HM,SOHND,PMMCF DEFAULT
15 Ramaraj 61 M 35952/11 Tongue-L T4N2bM0 U,S B,T,S,A L L SCC II UP PAL-RT DEFAULT
16 Chinniyan 42 M 36040/11 Lip-Lower T1N0M0 S S L VC P WLE,ERF ASYMPTAM
17 Raman 75 M 38084/11 Tongue-R T2N2bM0 U,S B,T C L SCC I UP HG,RND,POSTCRT ASYMPTAM
18 Angammal 65 F 38959/11 Buccal mucosa-L T2N1M0 U B,T L L SCC I U WLE,FHF,SOHND,POSTRT ASYMPTAM
19 Thayammal 65 F 39886/11 FOM T3N1M0 U,S.P B,T E L SCC I U CHEMORT ASYMPTAM
20 Sharmila 20 F 41077/11 Hard palate T3N1M0 U,P L SCC I U CHEMORT ASYMPTAM
21 Haridoss 59 M 41531/11 Buccal mucosa-L T4N2bM0 U,P,ES,DC B,T,S L L SCC II U CHEMORT DEFAULT
22 Selvanayagi 58 F 42175/11 Tongue-R T1N1M0 U,S B,T L L SCC I UP WLE,SOHND,POSTRT-HG RECURRENCE
23 Rajendran 73 M 42668/11 Tongue-L T4N3M0 U,LN B,T SMF L SCC III U PAL-RT DEFAULT
24 Dhanushram 58 M 44085/11 Tongue-R T3N1M0 U,S B,T,A L L SCC I UP CHEMORT ASYMPTAM
25 Mariammal 48 F 44105/11 Alveolus T2N0M0 U,P B,T L L SCC II U HM,SOHND,PMMCF ASYMPTAM
26 Jeyalakshmi 45 F 44110/11 Buccal mucosa-R T2N0M0 S B,T L L VC P WLE,FHF ASYMPTAM
27 Rajeswari 44 F 44154/11 Tongue-R T1N1M0 P,A,ES,U,S B,T SMF,L,E L SCC I UP HG,ESOHND,POSTRT ASYMPTAM
28 Kamatchi 49 M 44359/11 Lip-Upper T3N1M0 U B,S L SCC I U CHEMORT ASYMPTAM
29 David 45 M 44642/11 Tongue-L T2N0M0 U,S S L SCC I UP HG,SOHND,POSTRT ASYMPTAM
30 Pandiyan 50 M 45803/11 Buccal mucosa-R T4N2bM0 U,S,ES,DC B,A L SCC II UP CHEMORT DEFAULT
31 Kuppuswamy 65 M 45863/11 Tongue-L T4N2bM0 U B,T SMF,L,E L SCC III U PAL-RT DEFAULT
32 Ramesh Babu 48 M 47356/11 Tongue-R T4N2cM0 U,S B,S L SCC III UP PAL-RT DEATH
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33 Kathirvel 75 M 48746/11 Tongue-R T4N2bM0 ES,U B,T L SCC III U PAL-RT DEFAULT
34 Ramalingam 50 M 49006/11 Hard palate T3N1M0 U,P B,A L SCC I U CHEMORT ASYMPTAM
35 Muthulakshmi 45 F 49050/11 Tongue-L T4N2bM0 U B,T SMF L SCC II U PAL-RT DEFAULT
36 Thangamagil 47 F 49542/11 Alveolus T3N1M0 U,S,P B,T L L SCC I UP CHEMORT ASYMPTAM
37 Vaithdurai 52 M 50270/11 Buccal mucosa-L T4N2bM0 U,P,S,T,DC B,S,A E L SCC II UP CHEMORT DEFAULT
38 Saraswathi 67 F 50321/11 Buccal mucosa-R T3N1M0 U,ES B,T E L SCC I U CHEMORT ASYMPTAM
39 keemba 75 F 50646/11 Alveolus T3N1M0 U,P B,T L L SCC I U CHEMORT ASYMPTAM
40 Subbuthai 70 F 50858/11 Alveolus T3N1M0 U B,T L L SCC I U CHEMORT ASYMPTAM
41 Mookammal 35 F 52034/11 Tongue-R T2N2bM0 U L SCC I U HG,RND,POSTCRT ASYMPTAM
42 Chinnaponnu 50 F 52486/11 Buccal mucosa-L T1N0M0 U,S,ES B,T L L SCC II UP WLE,FHF DEFAULT
43 Pandi 60 M 52555/11 Buccal mucosa-L T3N1M0 U,S,ES B,T,S L L SCC I UP CHEMORT ASYMPTAM
44 Dharmar 48 M 52845/11 Buccal mucosa-R T4N2cM0 U,P,S,ES,RE B,S,A SMF L SCC III UP PAL-RT DEFAULT
45 Venkatraman 77 M 53412/11 Tongue-R T3N1M0 U B,T C L SCC I U CHEMORT ASYMPTAM
46 Periyaswamy 58 F 53728/11 Tongue-R T4N2cM0 S,ES,U B,T L SCC III UP PAL-RT DEFAULT
47 Leelavathi 40 F 53741/11 Buccal mucosa-L T4N2cM0 U,S,ES,OCF L SCC III UP PAL-RT DEFAULT
48 Kalyiammal 65 F 54283/11 Buccal mucosa-R T1N0M0 U,ES B,T E L SCC II U WLE,FHF ASYMPTAM
49 Shanmugam 48 M 54298/11 Tongue-R T4N2bM0 U B,S L SCC II U PAL-RT DEFAULT
50 Selvam 32 M 2766/12 Buccal mucosa-L T2N0M0 U,S,ES S,A E L SCC II UP WLE,FHF ASYMPTAM
51 Thangavel 63 M 55692/11 Tongue-L T2N2bM0 U,S B,T,S,A L L SCC I UP HG,RND,POSTCRT ASYMPTAM
52 Bhagavathy 62 F 56373/11 Tongue-R T3N1M0 S,ES,U B,T C L SCC I UP CHEMORT ASYMPTAM
53 Neelamegam 33 M 56500/11 Buccal mucosa-R T4N2bM0 U,RE S,A L SCC II U CHEMORT DEFAULT
54 Arumugam 55 M 56535/11 Tongue-L T4N3M0 U,LN B,T,A L L SCC III U PAL-RT DEFAULT
55 Parimala 57 F 56844/11 Tongue-R T4N2bM0 ES,U B,T C L SCC II U PAL-RT DEFAULT
56 Lakshmi 56 F 56871/11 Tongue-L T4N2bM0 U B,T L L SCC II U PAL-RT PROGR
57 Ponnuswamy 82 M 57323/11 Hard palate T3N0M0 U,P B,T E L SCC I U CHEMORT ASYMPTAM
58 Arulmanickam 48 M 58412/11 Tongue-R T2N0M0 P,A,ES,D,U B,S L SCC II U HG,SOHND DEFAULT
59 Soundammal 60 F 58444/11 Lip-Lower T2N0M0 U,S B,T E L SCC I UP WLE,FHF ASYMPTAM
60 Govindhammal 60 F 58724/11 Buccal mucosa-L T3N1M0 U,S,ES B,T L L SCC I UP CHEMORT ASYMPTAM
61 Alagammal 60 F 58967/11 Alveolus T4N2aM0 U,S,P B,T L L SCC II UP CHEMORT,CR,PMMCF,RND ASYMPTAM
62 Esaiyaiya Pillai 69 M 59893/11 Tongue-R T3N1M0 U B,T C L SCC I U CHEMORT ASYMPTAM
63 Rathinam 65 F 60213/11 Buccal mucosa-R T2N0M0 U B,T L L SCC I U WLE,DPF ASYMPTAM
64 Subbaiyan 58 M 60390/11 Buccal mucosa-R T4N2bM0 U,RE B,T,S E L SCC II U CHEMORT DEFAULT
65 Alagachi 50 F 60771/11 Tongue-R T4N2bM0 U B,T C L SCC II U PAL-RT PROGR
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66 Marisamy 63 M 61180/11 Hard palate T4N2bM0 U B,T,S,A L L SCC II U PAL-RT PROGR
67 Alagarswamy 70 M 61786/11 Tongue-R T4N2cM0 S,ES,U B,T L SCC III UP PAL-RT DEFAULT
68 Selvi 32 F 62322/11 Alveolus T4N2aM0 U,S L L SCC II UP CHEMORT DEFAULT
69 Murugammal 30 F 63657/11 Lip-Lower T3N1M0 U L SCC I UP CHEMORT ASYMPTAM
70 Ayyadurai 65 M 63925/11 Tongue-L T4N2bM0 U B,T SMF L SCC III U PAL-RT PROGR
71 Arumugan 67 M 65163/11 Buccal mucosa-R T2N0M0 S B,T L L VC P WLE,DPF ASYMPTAM
72 Sounthanadevi 63 F 66014/11 Buccal mucosa-R T3N1M0 U,ES B,T L L SCC I U CHEMORT ASYMPTAM
73 Ponnamal 63 F 66187/11 Tongue-R T2N0M0 ES,U B,T SMF L SCC I U HG,SOHND,POSTRT ASYMPTAM
74 Ramasamy 63 M 66292/11 Tongue-R T2N2bM0 U B,T,S,A L,E,SMF L SCC I U HG,RND-REC,CRT RECURRENCE
75 Kattuva 35 M 66487/11 Tongue-L T4N3M0 S,ES,U,LN S,A L SCC III UP PAL-RT DEFAULT
76 Sheikh Dawood 47 M 66796/11 Buccal mucosa-R T1N0M0 U S L SCC I U WLE-REC,RT RECURRENCE
77 Palaniappan 51 M 68383/11 Buccal mucosa-L T2N1M0 U,S,ES B,A L SCC I UP WLE,FHF,SOHND,POSTRT ASYMPTAM
78 Rajammal 44 F 68528/11 Tongue-L T1N1M0 U B,T SMF,L,E L SCC I U HG,SOHND,POSTRT RECURRENCE
79 Ramar 49 M 68543/11 Tongue-R T3N1M0 S,ES,U B,S L SCC I UP CHEMORT ASYMPTAM
80 Govindhaswamy 67 M 68729/11 Alveolus T3N1M0 U,S,P B,T L SCC I UP CHEMORT,HM,PMMCF ASYMPTAM
81 Selvam 48 M 68951/11 Tongue-R T2N2bM0 U B,S L SCC I U HG,RND,POSTCRT ASYMPTAM
82 Ganesan 55 M 69157/11 Buccal mucosa-R T2N0M0 S,ES,DC S,A L VC P WLE,FHF ASYMPTAM
83 Veeramalai 57 M 69685/11 Hard palate T3N0M0 U B,T,A L,E L SCC I U CHEMORT ASYMPTAM
84 Mohammed Hussain 60 M 69777/11 Buccal mucosa-L T2N0M0 U,S,ES B,T,S SMF L SCC II UP WLE,FHF ASYMPTAM
85 Dhashamurthy 68 M 70583/11 Tongue-L T4N2bM0 U B,T SMF L SCC III U PAL-RT PROGR
86 Manickam 40 M 70781/11 Buccal mucosa-R T4N2aM0 U,P,ES,DC S L SCC II U CHEMORT,CR,PMMCF,RND ASYMPTAM
87 Ponnuthai 70 F 71779/11 Buccal mucosa-L T2N0M0 U,ES B,T SMF L SCC II U WLE,FHF ASYMPTAM
88 Malaikannan 61 M 74452/11 Hard palate T3N1M0 U,S B,T,S L,E,SMF L SCC I UP CHEMORT DEFAULT
89  Jaleel Ahmed 32 M 74953/11 Tongue-R T4N2bM0 S,ES,U S,A L SCC II UP PAL-RT PROGR
90 Ramthai 50 F 75224/11 Buccal mucosa-R T4N2bM0 U,ES,DS,OCF B,T E L SCC II U PAL-RT PROGR
91 Periyakarupppan 63 M 753/11 Tongue-L T4N3M0 U,LN B,T,S,A E L SCC III U PAL-RT DEFAULT
92 Myilkalai 55 M 76589/11 Hard palate T3N1M0 U,S S,A L SCC I UP CHEMORT ASYMPTAM
93 Chinna Alagar 55 M 77593/11 Tongue-L T4N2aM0 U S,A L SCC II U CHEMORT,HG,CR,RND,PMMCF ASYMPTAM
94 Palaniammal 60 F 78712/11 Buccal mucosa-R T2NIM0 U,ES B,T L L SCC I U WLE,FHF,SOHND,POSTRT ASYMPTAM
95 Jeganathan 75 M 79387/11 Buccal mucosa-L T3N1M0 U,ES,DC B,T L L SCC I U CHEMORT,WLE,FHF,SOHND ASYMPTAM
96 Bashha 58 M 79488/11 Tongue-R T3N1M0 ES,U B,T,A L L SCC I U CHEMORT,HG,SOHND ASYMPTAM
97 Rajaram 63 M 79678/11 Lip-Lower T3N1M0 S,P,U B,T,S,A L L SCC I UP CHEMORT,WLE,ERF,SOHND ASYMPTAM
98 Palaniswamy 51 M 79834/11 Buccal mucosa-R T4N2bM0 U,S,RE,OCF B,A L SCC II UP PAL-RT PROGR
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99 Ponnan 68 M 79926/11 Buccal mucosa-L T4N2aM0 U,DS B,T L L SCC II U CHEMORT,CR,PMMCF,RND ASYMPTAM
100 Murugesan 54 M 8026/11 Hard palate T2N0M0 S S,A L ACA P WLE ASYMPTAM
101 Muvuyammal 31 F 80354/11 Lip-Lower T3N1M0 U L SCC I U CHEMORT,WLE,ERF,SOHND ASYMPTAM
102 Rajamanickam 67 M 81891/11 Alveolus T4N2aM0 U,RE B,T L L SCC II U CHEMORT DEFAULT
103 Balasubramaniyan 53 M 81917/11 FOM T2N2M0 U,P S,A L SCC I U CHEMORT ASYMPTAM
104 Muthulakshmi 55 F 83729/11 Alveolus T4N2aM0 U,S,P,T,RE B,T L L SCC II UP CHEMORT DEFAULT
105 Suruli 49 M 84010/11 Buccal mucosa-R T4N2bM0 U,S,RE B,A L SCC II UP PAL-RT PROGR
106 Karuppiah 59 M 90289/11 Tongue-L T4N2bM0 U B,T,S L,E L SCC II U PAL-RT PROGR
107 Perumaldesar 85 M 90690/11 Alveolus T3N1M0 U L SCC I U CHEMORT DEFAULT
108 Dhanabalan 52 M 92829/11 Buccal mucosa-L T3N1M0 U,DC B,S,A E L SCC I U CHEMORT DEFAULT
109 Rajan 55 M 10986/12 Buccal mucosa-R T4N2bM0 U S,A L SCC II U WLE,HM,PMMCF,RND,POSTCRT RECURRENCE
110 Duraipandi 61 M 11016/12 Alveolus T3N1M0 U B,T,S L L SCC I U CHEMORT DEFAULT
111 Balasubramani 50 M 1133/12 Buccal mucosa-L T4N2bM0 U,P,T,RE B,A L SCC II U PAL-RT PROGR
112  Guruswamy 65 M 12713/12 Tongue-L T1N0M0 U B,T,S,A L L SCC I U WLE,SOHND,POSTRT ASYMPTAM
113 Arokkiayammal 58 F 16714/12 Hard palate T3N0M0 U,S B,T E L SCC I UP CHEMORT ASYMPTAM
114 Mariyammal 65 F 16965/12 Buccal mucosa-R T3N1M0 U,DS B,T L L SCC I U CHEMORT DEFAULT
115 Nagammal 50 F 17963/12 Buccal mucosa-L T4N2bM0 U,P,T,RE B,T L L SCC II U PAL-RT PROGR
116 Balu 88 M 182303/12 Buccal mucosa-R T4N2bM0 U,S L MM CHEMO DEFAULT
117 Palanivel 56 M 18512/12 Tongue-R T2N0M0 P,A,ES,D,U B,T,A L L SCC II U HG,SOHND DEFAULT
118 Gandhi 70 M 18962/12 Hard palate T3N0M0 U,S B,T E L SCC I UP CHEMORT ASYMPTAM
119 Lakshmi 55 F 19363/12 FOM T4N2cM0 U,P B,T E L SCC III UP PAL-RT DEFAULT
120 Sellammal 45 F 19607/12 Alveolus T4N2bM0 U,S B,T L L SCC II UP CHEMORT,CR,PMMCF,RND ASYMPTAM
121 Sathasivam 60 M 19876/12 Tongue-R T4N2bM0 U B,T,S L,E L SCC II U PAL-RT DFFAULT
122 Janammal 70 M 1988/12 Tongue-L T4N2aM0 P,A,ES,D,U B,T SMF L SCC II U CHEMORT,HG,CR,RND,PMMCF DEFAULT
123 Veeraiya 47 M 20044/12 Tongue-L T4N2cM0 P,A,ES,D,U S L SCC III U PAL-RT DEFAULT
124 Nagarajan 65 M 21757/12 Buccal mucosa-L T4N2bM0 U,OCF B,T L L SCC III U PAL-RT PROGR
125 Ram 32 M 21761/12 Buccal mucosa-R T4N2bM0 U,P,T,RE S,A L SCC II U PAL-RT PROGR
126 Veeranan 52 M 2205/12 Buccal mucosa-L T4N2bM0 U,S,OCF B,S,A E L SCC II UP PAL-RT PROGR
127 Palanikumar 31 M 23134/12 Buccal mucosa-L T4N2bM0 U S,A E L SCC II U CHEMORT,CR,PMMCF,RND ASYMPTAM
128 Ampujam 60 F 24313/12 Buccal mucosa-R T3N1M0 U B,T L L SCC I U CHEMORT DEFAULT
129 Muthupandi 65 F 24625/12 Buccal mucosa-R T3N1M0 U B,T L L SCC I U CHEMORT DEFAULT
130 Ravikannan 40 M 24876/12 Buccal mucosa-L T3N1M0 U S L SCC I U CHEMORT DEFAULT
131 Duraisamy 67 F 24894/12 Tongue-R T4N2bM0 U B,T L SCC III U PAL-RT DEFAULT
MASTER CHART
132 Sengi 51 F 25697/12 Tongue-L T2N2bM0 U B,T SMF L SCC I U HG,RND,POSTCRT ASYMPTAM
133 Subramaniyan 63 M 26548/12 Tongue-R T4N2cM0 P,A,ES,D,U B,T,S,A L,E L SCC III U PAL-RT DEFAULT
134 Mary 27 F 29108/12 Tongue-R T4N2bM0 U L SCC II U PAL-RT DEFAULT
135 Pandiraj 67 M 30562/12 Buccal mucosa-R T2N0M0 S B,T L M VC P WLE,NLF ASYMPTAM
136 Sellambayiammal 60 F 30583/12 Lip-Lower T4N2cM0 U,S B,T SMF,L,E L SCC III U PAL-RT DEFAULT
137 Kannammal 55 F 31919/12 Alveolus T3N1M0 U,S B,T L L SCC I UP CHEMORT DEFAULT
138 Kamayam 66 F 34541/12 Alveolus T3N1M0 U,S B,T L L SCC I UP CHEMORT DEFAULT
139 Gabriel 75 M 34743/12 Buccal mucosa-L T3N1M0 U,S B,T L L SCC I UP CHEMORT DEFAULT
140 Pathar jems 75 M 34755/12 Tongue-R T2N0M0 U B,T C L SCC II U HG,SOHND DEFAULT
141 Kamalam 58 F 35899/12 Buccal mucosa-R T2N1M0 U B,T L L SCC I U WLE,FHF,SOHND,POSTRT ASYMPTAM
142 Madathi 75 F 35903/12 Buccal mucosa-L T2N1M0 U B,T L L SCC I U WLE,FHF,SOHND,POSTRT ASYMPTAM
143 Jothi 65 F 40655/12 Tongue-R T2N0M0 U B,T SMF L SCC I U HG,SOHND,POSTRT ASYMPTAM
144 Mariyappan 55 M 41468/12 Tongue-L T4N2cM0 P,A,ES,D,U S,A L SCC III U PAL-RT DEFAULT
145 Periyairulan 63 M 416266/12 Buccal mucosa-L T2N2bM0 U,S B,T,S,A L L SCC I UP WLE,DPF,RND,POSTCRT RECURRENCE
146 Katherasen 35 M 42621/12 FOM T4N2cM0 U,S S,A L SCC III UP PAL-RT DEFAULT
147 Sadaiyan 65 M 44144/12 Tongue-L T4N2aM0 U B,T,S,A L L SCC II U HG,HM,RND,PMMCF,POSTCRT DEATH
148 Karuppayee 70 F 48441/12 Buccal mucosa-L T4N2bM0 U B,T L L SCC III U CHEMORT DEFAULT
149 Karrupasamy 65 M 50577/12 Hard palate T4N2aM0 U,S B,T,S,A L L SCC II UP CHEMORT DEFAULT
150 Kattayan 26 M 53062/12 Buccal mucosa-L T4N2bM0 U L SCC II U CHEMORT DEFAULT
151 Magalakshmi 35 F 53217/12 Buccal mucosa-L T2N0M0 U L SCC I U WLE,FHF ASYMPTAM
152 Muthuraman 52 M 53700/12 Tongue-R T3N1M0 U B,S,A L,E L SCC I U CHEMORT DEFAULT
153 Rakkammal 60 F 54238/12 Buccal mucosa-L T3N1M0 U B,T L L SCC I U CHEMORT DEFAULT
154 Myileswari 40 F 54612/12 Lip-Upper T2N0M0 S L ACA P WLE,AF-FHF ASYMPTAM
155 Nagalingam 72 M 56031/12 RMT T3N0M0 P,T,U B,T SMF L SCC I U CHEMORT ASYMPTAM
156 Ezhaikkal 51 F 56031/12 Buccal mucosa-L T4N2bM0 U,P,T,DC B,T L L SCC II U CHEMORT DEFAULT
157 Subbulaksmi 61 F 56483/12 Hard palate T2N0M0 S B,T E L ACA P WLE DEFAULT
158 Kader basha 55 M 56877/12 Hard palate T4N2bM0 U S,A L SCC II U CHEMORT DEFAULT
159 Arputhamary 65 F 56877/12 Buccal mucosa-L T2N0M0 U B,T L L SCC I U WLE,FHF ASYMPTAM
160 Muniyasamy 63 M 59886/12 Tongue-R T4N2cM0 P,A,ES,D,U B,T,S,A L,E L SCC III U PAL-RT DEFAULT
161 Chinnathambi 55 M 71061/12 Alveolus T4N2aM0 U,T,RE S,A E L SCC II U CHEMORT DEFAULT
162 Nattan 72 M 71562/12 Hard palate T4N2aM0 U,S B,T E L SCC II UP CHEMORT DEFAULT
